Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 001-41512

SILO PHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada		27-3046338
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

677 N. Washington Boulevard,

Sarasota, Florida

34236

(Address of principal executive offices)

(Zip code)

(718) 400-9031
(Registrant’s telephone number, including area code)

560 Sylvan Avenue, Suite 3160,

Englewood Cliffs, New Jersey

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of common stock, par value $0.0001 per share, outstanding as of August 13, 2024 was: 4,484,456 (355,710 shares held in treasury).

SILO PHARMA, INC. AND SUBSIDIARY
FORM 10-Q
JUNE 30, 2024

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
	Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023	1
	Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)	2
	Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)	3
	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (Unaudited)	4
	Notes to Consolidated Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	38
Item 4.	Mine Safety Disclosures	38
Item 5.	Other Information	38
Item 6.	Exhibits	38

SIGNATURES		39

-i-

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,”, “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “project,” “continue,” “potential,” “ongoing” or the negative of these terms or other comparable terminology.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report on Form 10-Q. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to:

●

our ability to obtain additional funds for our operations;

●

our financial performance;

●

risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;

●

risks related to market acceptance of products;

●

intellectual property risks;

●

the impact of government regulation and developments relating to our competitors or our industry;

●

our competitive position;

●

our industry environment;

●

our anticipated financial and operating results, including anticipated sources of revenues;

●

assumptions regarding the size of the available market, benefits of our products, product pricing and timing of product launches;

●

our estimates of our expenses, losses, future revenue and capital requirements, including our needs for additional financing;

●

our ability to attract and retain qualified key management and technical personnel;

●

statements regarding our goals, intensions, plans and expectations, including the introduction of new products and markets;

●

our cash needs and financing plans.

These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled “Risk Factors” and elsewhere in this report.

Any forward-looking statement in this report reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this report completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

This report also contains estimates, projections and other information concerning our industry, our business and our markets, including data regarding the estimated size of those markets and their projected growth rates. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, and general publications, government data and similar sources. While we believe that the reports, research surveys, studies and similar data prepared by third parties are reliable, we have not independently verified the data contained in them.

You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake any obligation to update or release any revisions to these forward-looking statements to reflect any events or circumstances, whether as a result of new information, future events, changes in assumptions or otherwise, after the date hereof. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

-ii-

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SILO PHARMA, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2024			2023
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	4,506,300		$	3,524,308
Short-term investments		3,102,240			4,140,880
Prepaid expenses and other current assets		120,288			15,970

Total Current Assets		7,728,828			7,681,158

LONG-TERM ASSETS:
Prepaid expenses and other assets - non-current		62,064			64,983
Intangible assets, net		247,400			-

Total Long-Term Assets		309,464			64,983

Total Assets	$	8,038,292		$	7,746,141

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	1,250,777		$	703,488
Deferred revenue - current portion		72,102			72,102

Total Current Liabilities		1,322,879			775,590

LONG TERM LIABILITIES:
Deferred revenue - long-term portion		757,629			793,680

Total Long Term Liabilities		757,629			793,680

Total Liabilities		2,080,508			1,569,270

Commitment and Contingencies (see Note 8)

STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of June 30, 2024 and December 31, 2023
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,076,528 and 3,159,096 shares issued and 3,720,818 and 2,906,241 shares outstanding at June 30, 2024 and December 31, 2023, respectively		408			316
Additional paid-in capital		19,198,841			17,525,714
Treasury stock, at cost (355,710 and 252,855 shares on June 30, 2024 and December 31, 2023, respectively)		(644,234	)		(471,121	)
Accumulated other comprehensive income (loss)		8,026			(6,227	)
Accumulated deficit		(12,605,257	)		(10,871,811	)

Total Stockholders’ Equity		5,957,784			6,176,871

Total Liabilities and Stockholders’ Equity	$	8,038,292		$	7,746,141

See accompanying notes to unaudited consolidated financial statements.

-1-

SILO PHARMA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2024			2023			2024			2023

LICENSE FEE REVENUE	$	18,025		$	18,025		$	36,051		$	36,051

COST OF REVENUES		1,459			1,459			2,919			2,919

GROSS PROFIT		16,566			16,566			33,132			33,132

OPERATING EXPENSES:
Compensation expense		168,381			169,186			341,727			331,443
Professional fees		386,465			570,295			641,067			935,565
Research and development		392,824			130,719			774,889			333,632
Insurance expense		21,101			22,251			42,805			46,896
Selling, general and administrative expenses		50,569			239,100			114,931			304,066

Total operating expenses		1,019,340			1,131,551			1,915,419			1,951,602

LOSS FROM OPERATIONS		(1,002,774	)		(1,114,985	)		(1,882,287	)		(1,918,470	)

OTHER INCOME (EXPENSE):
Interest and dividend income, net		77,042			109,584			165,219			173,972
Interest expense		(1,859	)		(1,863	)		(3,729	)		(3,518	)
Net realized loss on short-term investments		(1,259	)		(2,179	)		(1,025	)		(2,179	)
Penalty from early termination of certificate of deposit		-			-			-			(166,034	)
Net unrealized loss on equity investments		-			(3,508	)		-			(3,118	)
Foreign currency transaction loss		(2,929	)		-			(11,624	)		-

Total other income (expense)		70,995			102,034			148,841			(877	)

LOSS BEFORE PROVISION FOR INCOME TAXES		(931,779	)		(1,012,951	)		(1,733,446	)		(1,919,347	)

Provision for income taxes		-			-			-			-

NET LOSS	$	(931,779	)	$	(1,012,951	)	$	(1,733,446	)	$	(1,919,347	)

COMPREHENSIVE LOSS:
Net loss	$	(931,779	)	$	(1,012,951	)	$	(1,733,446	)	$	(1,919,347	)

Other comprehensive income (loss):
Unrealized (loss) income on short-term investments		(18,078	)		(8,520	)		14,253			(3,281	)

Total comprehensive loss	$	(949,857	)	$	(1,021,471	)	$	(1,719,193	)	$	(1,922,628	)

NET LOSS PER COMMON SHARE:
Basic and diluted	$	(0.31	)	$	(0.32	)	$	(0.59	)	$	(0.61	)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted		3,052,666			3,153,852			2,959,800			3,156,311

See accompanying notes to unaudited consolidated financial statements.

-2-

SILO PHARMA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

(Unaudited)

					Additional							Accumulated Other						Total
	Common Stock				Paid In		Treasury Stock					Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		Shares		Amount			Income (Loss)			Deficit			Equity

Balance, December 31, 2023		3,159,096	$	316	$	17,525,714		252,855	$	(471,121	)	$	(6,227	)	$	(10,871,811	)	$	6,176,871

Purchase of treasury stock		-		-		-		72,790		(115,452	)		-			-			(115,452	)

Accumulated other comprehensive income - short-term investments		-		-		-		-		-			32,331			-			32,331

Net loss		-		-		-		-		-			-			(801,667	)		(801,667	)

Balance, March 31, 2024		3,159,096		316		17,525,714		325,645		(586,573	)		26,104			(11,673,478	)		5,292,083

Sale of common stock and pre-funded warrants		883,395		89		1,673,127		-		-			-			-			1,673,216

Exercise of pre-funded warrants		34,037		3		-		-		-			-			-			3

Purchase of treasury stock		-		-		-		30,065		(57,661	)		-			-			(57,661	)

Accumulated other comprehensive loss - short-term investments		-		-		-		-		-			(18,078	)		-			(18,078	)

Net loss		-		-		-		-		-			-			(931,779	)		(931,779	)

Balance, June 30, 2024		4,076,528	$	408	$	19,198,841		355,710	$	(644,234	)	$	8,026		$	(12,605,257	)	$	5,957,784

							Additional									Accumulated Other						Total
	Common Stock						Paid In			Treasury Stock						Comprehensive			Accumulated			Stockholders’
	Shares			Amount			Capital			Shares			Amount			Income (Loss)			Deficit			Equity

Balance, December 31, 2022		3,158,797		$	316		$	17,511,589			-		$	-		$	-		$	(7,171,128	)	$	10,340,777

Accretion of stock options expense to stock based compensation		-			-			4,237			-			-			-			-			4,237

Accumulated other comprehensive income - short-term investments		-			-			-			-			-			5,239			-			5,239

Net loss		-			-			-			-			-			-			(906,396	)		(906,396	)

Balance, March 31, 2023		3,158,797			316			17,515,826			-			-			5,239			(8,077,524	)		9,443,857

Accretion of stock options expense to stock based compensation		-			-			4,237			-			-			-			-			4,237

Purchase of treasury stock		-			-			-			57,335			(130,959	)		-			-			(130,959	)

Cancellation of treasury stock		(50,000	)		(5	)		(114,753	)		(50,000	)		114,758			-			-			-

Accumulated other comprehensive loss - short-term investments		-			-			-			-			-			(8,520	)		-			(8,520	)

Net loss		-			-			-			-			-			-			(1,012,951	)		(1,012,951	)

Balance, June 30, 2023		3,108,797		$	311		$	17,405,310			7,335		$	(16,201	)	$	(3,281	)	$	(9,090,475	)	$	8,295,664

See accompanying notes to unaudited consolidated financial statements.

-3-

SILO PHARMA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Six Months Ended
	June 30,
	2024			2023

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,733,446	)	$	(1,919,347	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation and professional fees		-			8,474
Amortization of prepaid stock-based professional fees		-			67,550
Net realized loss on short-term investments		1,025			2,179
Net unrealized loss on equity investments		-			3,118
Change in operating assets and liabilities:
Prepaid expenses and other current assets		(101,399	)		(50,071	)
Interest receivable		-			(2,380	)
Accounts payable and accrued expenses		299,889			683,874
Deferred revenue		(36,051	)		(36,051	)

NET CASH USED IN OPERATING ACTIVITIES		(1,569,982	)		(1,242,654	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Sale of short-term investments		1,149,320			517,821
Purchase of short-term investments		(97,452	)		(10,352,410	)

NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES		1,051,868			(9,834,589	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock and pre-funded warrants		1,673,216			-
Proceeds from exercise of pre-funded warrants		3			-
Purchase of treasury stock		(173,113	)		(130,959	)

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		1,500,106			(130,959	)

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		981,992			(11,208,202	)

CASH AND CASH EQUIVALENTS - beginning of the period		3,524,308			11,367,034

CASH AND CASH EQUIVALENTS - end of the period	$	4,506,300		$	158,832

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	3,729		$	3,518
Income taxes	$	-		$	-

Non-cash investing and financing activities:
Change in accumulated other comprehensive income	$	14,253		$	3,281
Cancellation of treasury stock	$	-		$	114,758
Intangible assets acquired with accounts payable	$	247,400		$	-

See accompanying notes to unaudited consolidated financial statements.

-4-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

NOTE 1 – ORGANIZATION AND BUSINESS

Silo Pharma, Inc. (the “Company”) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January 24, 2013, the Company changed its state of incorporation from New York to Delaware. On December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of Nevada.

The Company is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The Company seeks to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, post-traumatic stress disorder (“PTSD”), Alzheimer’s, Parkinson’s, and other rare neurological disorders. The Company’s mission is to identify assets to license and fund the research which the Company believes will be transformative to the well-being of patients and the health care industry. The Company was previously engaged in the development of a streetwear apparel brand, NFID (see below).

On May 21, 2019, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter, on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Uppercut Brands, Inc. to Silo Pharma, Inc.

On April 8, 2020, the Company incorporated a new wholly-owned subsidiary, Silo Pharma Inc., in the State of Florida. The Company has also secured the domain name www.silopharma.com. The Company had been exploring opportunities to expand the Company’s business by seeking to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. In July 2020, through the Company’s newly formed subsidiary, the Company entered into a commercial evaluation license and option agreement with University of Maryland, Baltimore (“UMB”) (see Note 8) pursuant to which, among other things, UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master License Agreement with UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand the Company’s business to focus on this line of business.

On September 30, 2021, the Company entered into and closed on an Asset Purchase Agreement (the “Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company (the “Buyer”), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company’s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bore 8% interest per annum and matured on October 1, 2023. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into a First Amendment Promissory Note which increased the interest rate to 9% per annum and extended the maturity date to December 30, 2023 for no consideration. On December 30, 2023, the buyer defaulted on the promissory note (See Note 4).

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 25, 2024.

The Company’s unaudited consolidated financial statements include financial statements for Silo Pharma, Inc. and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc. All intercompany transactions and balances have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited consolidated financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for the periods presented.

-5-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Liquidity

As reflected in the accompanying unaudited consolidated financial statements, the Company generated a net loss of $1,733,446 and used cash in operations of $1,322,582 during the six months ended June 30, 2024. Additionally, the Company has an accumulated deficit of $12,605,257 on June 30, 2024. As of June 30, 2024, the Company had working capital of $6,405,949.

The positive working capital serves to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern. The Company believes that the Company has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.

Use of Estimates

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the six months ended June 30, 2024 and 2023 include the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments, valuation allowances for deferred tax assets, and the fair value of shares and stock options issued for services.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits. On June 30, 2024 and December 31, 2023, the Company had cash in excess of FDIC limits of approximately $3,756,000 and $2,805,000, respectively. In connection with the early termination of a certificate of deposit, during the six months ended June 30, 2023, the Company paid a penalty of $166,034, which is reflected on the accompanying unaudited consolidated statement of operations and comprehensive loss. Any material loss that we may experience in the future could have an adverse effect on our ability to pay our operational expenses or make other payments.

Short-Term Investments

The Company’s portfolio of short-term investments consists of marketable debt securities which are comprised solely of highly rated U.S. government securities with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the unaudited consolidated balance sheet and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income and as a component of the unaudited consolidated statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income (expense), net in the unaudited consolidated statements of operations and comprehensive loss.

An impairment loss may be recognized when the decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis.

The Company recorded $(18,078) and $14,253 of unrealized (loss) income on short-term investments as a component of accumulated other comprehensive income (loss) for the three and six months ended June 30, 2024, respectively. The Company recorded $(8,520) and $(3,281) of unrealized loss as a component of accumulated other comprehensive loss for the three and six months ended June 30, 2023, respectively.

-6-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Equity Investments, at Fair Value

Realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s carrying value and the net proceeds received from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized gains or losses are computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying value at the beginning of the period and the fair value at the end of the period. As of June 30, 2024 and December 31, 2023, the Company had no such investments.

Note Receivable

The Company recognizes an allowance for losses on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recorded as part of general and administrative expenses. As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest receivable in an amount equal to the estimated probable losses, and accordingly, the Company recorded bad debt expense of $69,600, which represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600. As of June 30, 2024, there were no subsequent collections of previously written-off notes receivable.

Prepaid Expenses

Prepaid expenses and other current assets of $120,288 and $15,970 on June 30, 2024 and December 31, 2023, respectively, consist primarily of costs paid for future services which will occur within a year. On June 30, 2024 and December 31, 2023, prepaid expenses and other assets – non-current amounted to $62,064 and $64,983, respectively, and consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash and equity instruments for consulting, research and development, license fees, public relations and business advisory services, and legal fees which are being amortized over the terms of their respective agreements, which may exceed a year of service.

Intangible Assets

Intangible assets, consisting of an exclusive license agreement, are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful life of 20 years, less any impairment charges. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

Revenue Recognition

The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.

The Company records interest and dividend income on an accrual basis to the extent that the Company expects to collect such amounts.

For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license agreement (see Note 8).

Cost of Revenues

The primary components of cost of revenues on license fees includes the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid expense to be amortized over the term of the related license agreement (see Note 8).

Stock-Based Compensation

Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation – Stock Compensation”, which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting Standards Update (“ASU”) 2016-09 Improvements to Employee Share-Based Payment.

-7-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Income Taxes

Deferred income tax assets and liabilities arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company follows the provisions of Financial Accounting Standards Board (“FASB”) ASC 740-10, “Uncertainty in Income Taxes”. Certain recognition thresholds must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax positions that meet a “more-likely-than-not” threshold. The Company does not believe it has any uncertain tax positions as of June 30, 2024 and December 31, 2023 that would require either recognition or disclosure in the accompanying unaudited consolidated financial statements.

Research and Development

In accordance with ASC 730-10, “Research and Development-Overall,” research and development costs are expensed when incurred. During the six months ended June 30, 2024 and 2023, research and development costs were $774,889 and $333,632, respectively. During the three months ended June 30, 2024 and 2023, research and development costs were $392,824 and $130,719, respectively.

Leases

Leases are accounted for using ASU 2016-02, “Leases (Topic 842)”. ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to recognize a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. As of June 30, 2024 and December 31, 2023, the Company has no leases. The Company will analyze any lease to determine if it would be required to record a lease liability and a right of use asset on its unaudited consolidated balance sheets at fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less.

Net Loss per Common Share

Basic loss per share is computed by dividing net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially dilutive securities which include stock options and stock warrants are excluded from the computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company’s net losses.

The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the six months ended June 30, 2024 and 2023:

	June 30,		June 30,
	2024		2023
Stock options		26,850		28,850
Warrants		1,390,819		404,580
		1,417,669		433,430

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s unaudited consolidated financial statements.

-8-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

NOTE 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Fair Value Measurements and Fair Value of Financial Instruments

FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on June 30, 2024 and December 31, 2023. Accordingly, the estimates presented in these unaudited consolidated financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).

	Level 1 -	Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

	Level 2 -	Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

	Level 3 -	Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying value of certain financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, notes receivable, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (the “FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023.

	June 30, 2024						December 31, 2023
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Short-term investments	$	3,102,240	$	-	$	-	$	4,140,880	$	-	$	-

The Company’s short-term investments and equity investments are level 1 measurements and are based on redemption value at each date.

Short-Term Investments – Debt Securities, at Fair Value

The following table summarizes activity in the Company’s short-term investments, at fair value for the periods presented:

	Six Months Ended June 30,			Six Months Ended June 30,
	2024			2023
Balance, beginning of period	$	4,140,880		$	-
Additions		97,452			10,352,410
Sales at original cost		(1,149,320	)		(517,821	)
Net realized loss on short-term investments		(1,025	)		(2,179	)
Unrealized gain (loss)		14,253			(3,281	)
Balance, end of period	$	3,102,240		$	9,829,129

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.

-9-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

NOTE 4 – NOTE RECEIVABLE

On June 30, 2024 and December 31, 2023, note receivable consisted of the following:

	June 30,			December 31,
	2024			2023
Principal amount of note receivable	$	60,000		$	60,000
Accrued interest receivable		9,600			9,600
Subtotal		69,600			69,600
Less: allowance for doubtful accounts		(69,600	)		(69,600	)
Note receivable – current		-			-

As of December 31, 2023, the Company recognized an allowance for loss on the note receivable and accrued interest receivable in an amount equal to the estimated probable losses of $69,600, which represents the note receivable principal balance of $60,000 and accrued interest receivable of $9,600. As of June 30, 2024, there were no subsequent collections of previously written-off notes receivable.

NOTE 5 – INTANGIBLE ASSETS

On July 1, 2024, the Company entered into an exclusive license agreement (the “Columbia License Agreement”) with Columbia University (“Columbia”) with an effective date of June 28, 2024 (the “Effective Date”) and pursuant to which the Company has been granted exclusive rights to certain patents and technical information to develop, manufacture and commercialize Products (as defined in the Columbia License Agreement), including therapies for stress-induced affective disorders and other conditions for a cost of $247,400, which has been accrued as of June 30, 2024 and included in accounts payable and accrued expenses on the accompanying unaudited consolidated balance sheet. The term of the Columbia License Agreement shall commence on the Effective Date and shall continue on a country-by-country and product-by-product basis until the latest of: (a) the date of expiration of the last to expire of the issued Patents (as defined in the Columbia License Agreement), (b) 20 years after the first bona fide commercial sale of the Product in the country in question, or (c) expiration of any market exclusivity period granted by a regulatory agency for a Product in the country in question (See Note 8).

On June 30, 2024 and December 31, 2023, intangible assets consisted of the following:

	Useful life	June 30, 2024		December 31, 2023
License	20 years	$	247,400	$	-
Less: accumulated amortization			-		-
		$	247,400	$	-

Amortization of intangible assets with finite lives attributable to future periods is as follows:

Year ending June 30:	Amount
2025	$	12,370
2026		12,370
2027		12,370
2028		12,370
2029		12,370
Thereafter		185,550
Total	$	247,400

-10-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

NOTE 6 – STOCKHOLDERS’ EQUITY

Shares Authorized

On December 4, 2023, stockholders of the Company approved a decrease to the number of authorized shares of the Company’s common stock from 500,000,000 shares to 100,000,000 shares. On December 4, 2023, the Company filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation with the Delaware Secretary of State to decrease its authorized shares of common stock from 500,000,000 shares to 100,000,000 shares. On December 19, 2023, the Company reincorporated as a Nevada corporation and filed Articles of Incorporation with the Nevada Secretary of State on such date. The Company has 105,000,000 shares authorized which consist of 100,000,000 shares of common stock and 5,000,000 shares of preferred stock.

Common Stock Issued for Services

On August 29, 2022, the Company entered into a one-year consulting agreement with an entity for investor relations services. In connection with this consulting agreement, the Company issued 20,000 restricted common shares of the Company to the consultant. These shares vest immediately. These shares were valued at $135,100, or $6.755 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement, during the six months ended June 30, 2024 and 2023, the Company recorded stock-based professional fees of $0 and $67,550, respectively.

Sale of Common Stock and Warrants

On June 4, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 883,395 shares (the “Shares”) of common stock of the Company (the “Common Stock”) at a purchase price of $2.18 per share of Common Stock, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 34,037 shares of Common Stock of the Company (the “Pre-Funded Warrant Shares”), having an exercise price of $0.0001 per share, and a purchase price of $2.1799 per Pre-Funded Warrant (the “Offering”). The shares of Common Stock and Pre-Funded Warrants (and shares of common stock underlying the Pre-Funded Warrants) were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-276658), which was declared effective by the Securities and Exchange Commission on January 30, 2024.

Concurrently with the sale of Common Stock and/or the Pre-Funded Warrants, pursuant to the Purchase Agreement in a private placement, for each share of Common Stock and/or Pre-Funded Warrant purchased by the investors, such investors received from the Company an unregistered warrant (the “Common Warrant”) to purchase one share of Common Stock (the “Common Warrant Shares”). Accordingly, the Company issued an aggregate of 917,432 Common Warrants to the Investors. The Common Warrants have an exercise price of $2.06 per share and are exercisable immediately upon issuance for a five-year period.

On April 23, 2024, the Company entered into an engagement agreement with H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as placement agent on a reasonable “best efforts” basis in connection with the Offering. The Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.5% of the gross proceeds from the sale of securities in the Offering and a management fee equal to 1.0% of the gross proceeds raised in the Offering. The Company also agreed to issue the Placement Agent (or its designees) a warrant (the “Placement Agent Warrant”) to purchase up to 7.5% of the aggregate number of shares of Common Stock and/or Pre-Funded Warrants sold in the offering, In connection with the June 4, 2024 Purchase Agreement, the Company paid the Placement Agent a cash fee and management fee of $170,000 and the Placement Agent received Placement Agent Warrants to purchase up to 68,807 shares of Common Stock, at an exercise price equal to 125.0% of the offering price per share of Common Stock, or $2.725 per share. The Placement Agent Warrants are exercisable immediately upon issuance for a period of five years following the commencement of the sales pursuant to the Offering. In addition, the Company paid the Placement Agent $25,000 for non-accountable expenses, $50,000 for legal expenses and other out-of-pocket expenses and $15,950 for clearing fees.

The closing of the sales of these securities under the Purchase Agreement took place on June 6, 2024. The public offering price for each share of Common Stock was $2.18 for aggregate gross proceeds of $1,925,801, and public offering price for the Pre-Funded Warrants was $2.1799 for each Pre-Funded Warrant for aggregate gross proceeds of $74,201. In connection with this Offering, the Company raised aggregate gross proceeds of $2,000,002 and received net proceeds of $1,673,216, net of Underwriters discounts and offering costs of $260,950 and legal fees of $65,833. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

-11-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

The per share exercise price for the Pre-Funded Warrants was $0.0001 and the Pre-Funded Warrants were exercisable immediately. The Underwriters immediately exercised the 34,037 Pre-Funded Warrants and the Underwriters received 34,037 shares of Common Stock for cash of $3. The Pre-Funded Warrants are not and will not be listed for trading on any national securities exchange or other nationally recognized trading system.

The Common Warrants and the Common Warrant Shares were sold without registration under the Securities Act of 1933 (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Pursuant to the terms of the Purchase Agreement and subject to certain exceptions as set forth in the Purchase Agreement, from the date of the Purchase Agreement until fifteen (15) days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. In addition, until the one year from the Closing Date, the Company is prohibited from entering into a Variable Rate Transaction (as defined in the Purchase Agreement), subject to certain limited exceptions.

The Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale of the Common Warrant Shares (the “Resale Registration Statement”) within 45 calendar days of the date of the Purchase Agreement (the “Filing Date”), and to use commercially reasonable efforts to cause the Resale Registration Statement to be declared effective by the SEC within 60 calendar days following the date of the Filing Date and to keep the Resale Registration Statement effective at all times until the Holders no longer own any Common Warrants or Common Warrant Shares.

Stock Repurchase Plan

On January 26, 2023, the Company’s Board of Directors authorized a stock repurchase plan to repurchase up to $1 million of the Company’s issued and outstanding common stock, from time to time, with such plan to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company’s common stock until March 31, 2024, on April 4, 2024, the Stock Repurchase Plan was extended to April 30. During the year ended December 31, 2023, the Company purchased 252,855 shares of common stock for a cost of $471,121, which is reflected in treasury stock on the accompanying unaudited consolidated balance sheet. During the six months ended June 30, 2024, the Company purchased 102,855 shares of common stock for a cost of $173,113. As of June 30, 2024, the Company has repurchased an aggregate of 355,710 shares of its common stock for a total cost of $644,234 pursuant to its Stock Repurchase Program.

Stock Options

On January 18, 2021, the Company’s board of directors (“Board”) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) to incentivize employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash, stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation units and other stock or cash-based awards. The 2020 Plan shall terminate on the tenth anniversary of the date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason. An amendment of the 2020 Plan shall be subject to the approval of the Company’s stockholders only to the extent required by applicable laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders. On September 15, 2023, our Board of Directors adopted the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan which was approved by the Company’s stockholders on December 4, 2023. The Amended and Restated Omnibus Equity Incentive Plan (i) increases the number of shares of common stock that may be issued under such plan by 300,000 shares to 470,000 shares and (ii) includes clawback provisions to comply with recent developments of applicable law.

-12-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

During the six months ended June 30, 2024 and 2023, the Company amortized $0 and $8,474 of the deferred compensation which was recorded as compensation expense in the accompanying unaudited consolidated statement of operations and comprehensive loss, respectively. As of June 30, 2024 and December 31, 2023, there were no remaining deferred compensation costs.

Stock option activities for the six months ended June 30, 2024 are summarized as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance Outstanding, December 31, 2023		28,850		$	7.28		5.31	$	8,610
Expired		(2,000	)		0.005		-		-
Balance Outstanding, June 30, 2024		26,850		$	7.82		5.19	$	3,980
Exercisable, June 30, 2024		26,850		$	7.82		5.19	$	3,980

Stock Warrants

As discussed above, on June 4, 2024, the Company Pre-Funded Warrants to purchase up to 34,037 shares of Common Stock of the Company, having an exercise price of $0.0001 per share, and a purchase price of $2.1799 per Pre-Funded Warrant, The per share exercise price for the Pre-Funded Warrants was $0.0001 and the Pre-Funded Warrants were exercisable immediately. The Underwriters immediately exercised the 34,037 Pre-Funded Warrants and the Underwriters received 34,037 shares of Common Stock for cash of $3.

On June 4, 2024, concurrently with the sale of Common Stock and/or the Pre-Funded Warrants, pursuant to the Purchase Agreement in a private placement as discussed above, the Company issued an aggregate of 917,432 Common Warrants to the Investors. The Common Warrants have an exercise price of $2.06 per share and are exercisable immediately upon issuance for a five-year period. Additionally, the Placement Agent received Placement Agent Warrants to purchase up to 68,807 shares of Common Stock, at an exercise price equal to 125.0% of the offering price per share of Common Stock, or $2.725 per share. The Placement Agent Warrants are exercisable immediately upon issuance for a period of five years.

Warrant activities for the six months ended June 30, 2024 are summarized as follows:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance Outstanding, December 31, 2023		404,580		$	14.05		2.31	$	-
Granted		1,020,276			2.04		-		-
Exercised		(34,037	)		0.0001
Balance Outstanding, June 30, 2024		1,390,819		$	5.58		4.03	$	-
Exercisable, June 30, 2024		1,390,819		$	5.58		4.03	$	-

NOTE 7 – CONCENTRATIONS

Customer concentration

For the six months ended June 30, 2024 and 2023, one licensee accounted for 100% total revenues from customer license fees.

Vendor concentrations

For the six months ended June 30, 2024, two licensors accounted for 100% of the Company’s vendor license agreements (see Note 8) related to the Company’s biopharmaceutical operations. For the six months ended June 30, 2023, one licensor accounted for 100% of the Company’s vendor license agreements (see Note 8) related to the Company’s biopharmaceutical operations.

-13-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

NOTE 8 – COMMITMENTS AND CONTINGENCIES

Employment Agreements

Eric Weisblum

On October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the “2022 Weisblum Employment Agreement”) pursuant to which Mr. Weisblum’s (i) base salary will be $350,000 per year, (ii) Mr. Weisblum was paid a one-time signing bonus of $100,000, and (iii) Mr. Weisblum shall be entitled to receive an annual bonus of up to $350,000, subject to the sole discretion of the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”), and upon the achievement of additional criteria established by the Compensation Committee from time to time (the “Annual Bonus”). In addition, pursuant to the 2022 Weisblum Employment Agreement, upon termination of Mr. Weisblum’s employment for death or Total Disability (as defined in the 2022 Weisblum Employment Agreement), in addition to any accrued but unpaid compensation and vacation pay through the date of his termination and any other benefits accrued to him under any Benefit Plans (as defined in the 2022 Weisblum Employment Agreement) outstanding at such time and the reimbursement of documented, unreimbursed expenses incurred prior to such termination date (collectively, the “Weisblum Payments”), Mr. Weisblum shall also be entitled to the following severance benefits: (i) 24 months of his then base salary; (ii) if Mr. Weisblum elects continuation coverage for group health coverage pursuant to COBRA Rights (as defined in the 2022 Weisblum Employment Agreement), then for a period of 24 months following Mr. Weisblum’s termination he will be obligated to pay only the portion of the full COBRA Rights cost of the coverage equal to an active employee’s share of premiums (if any) for coverage for the respective plan year; and (iii) payment on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which Mr. Weisblum was a participant as of the date of his termination (together with the Weisblum Payments, the “Weisblum Severance”). Furthermore, pursuant to the 2022 Weisblum Employment Agreement, upon Mr. Weisblum’s termination (i) at his option (A) upon 90 days prior written notice to the Company or (B) for Good Reason (as defined in the 2022 Weisblum Employment Agreement), (ii) termination by the Company without Cause (as defined in the 2022 Weisblum Employment Agreement) or (iii) termination of Mr. Weisblum’s employment within 40 days of the consummation of a Change in Control Transaction (as defined in the Weisblum Employment Agreement), Mr. Weisblum shall receive the Weisblum Severance; provided, however, Mr. Weisblum shall be entitled to a pro-rated Annual Bonus of at least $200,000. In addition, any equity grants issued to Mr. Weisblum shall immediately vest upon termination of Mr. Weisblum’s employment by him for Good Reason or by the Company at its option upon 90 days prior written notice to Mr. Weisblum, without Cause. In September 2023 and October 2022, the Company paid a bonus of $200,000 and $100,000 to Mr. Weisblum, respectively.

Daniel Ryweck

On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company. On September 28, 2022, the Company entered into an employment agreement (the “Ryweck Employment Agreement”) with Mr. Ryweck. Pursuant to the terms of the Ryweck Employment Agreement, which was amended on October 12, 2022, Mr. Ryweck will (i) receive a base salary at an annual rate of $60,000 (the “Base Compensation”) payable in equal monthly installments, and (ii) be eligible to receive an annual discretionary bonus. The term of Mr. Ryweck’s engagement under the Ryweck Employment Agreement commenced on September 28, 2022 and continued until September 28, 2023, unless earlier terminated in accordance with the terms of the Ryweck Employment Agreement. The term of Mr. Ryweck’s Employment Agreement was automatically renewed until September 28, 2024 and will automatically renew for successive one-year periods until terminated by Mr. Ryweck or the Company.

Dr. James Kuo

On January 27, 2022, the Company and Dr. James Kuo entered into an employment agreement (“Kuo Employment Agreement”) for Dr. Kuo to serve as the Vice President of Research & Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days prior to the applicable renewal date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (“Board”) and shall be payable at the Company’s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vested as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vested on October 31, 2022 and; (iii) 5,000 vested on October 31, 2023. The 16,000 stock options had a fair value of $94,915 which valued at grant date using Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 1.18%, expected dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 117% based on calculated volatility. The Company recorded the fair value of the stock options, in the amount of $94,915, as deferred compensation which is being amortized over the vesting period. During the six months ended June 30, 2024 and 2023, the Company amortized $0 and $8,474 of the deferred compensation which was recorded as compensation expenses in the unaudited consolidated statement of operations and comprehensive loss, respectively. As of June 30, 2024 and December 31, 2023, there was no remaining deferred compensation related to these issuances. (see Note 6).

-14-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

License Agreements between the Company and Vendors

University of Maryland, Baltimore - License Agreement for Development and Use of Central Nervous System-Homing Peptides

Commercial Evaluation License and Option Agreement with the University of Maryland, Baltimore

Effective as of July 15, 2020, the Company, through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (“UMB”) (collectively as “Parties”), entered into a commercial evaluation license and option agreement (“License Agreement”), granting the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (“Exclusive Option”) with respect to the subject technology. The License Agreement had a term of six months from the effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate this agreement within thirty days by giving written notice.

University of Maryland, Baltimore - License Agreement for Development and Use of Joint-Homing Peptides

Commercial Evaluation License and Option Agreement with the University of Maryland, Baltimore

Effective as of February 26, 2021, the Company, through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (“UMB”) (collectively as “Parties”), entered into a commercial evaluation license and option agreement (“License Agreement”), which granted the Company an exclusive, non-sublicensable, non-transferable license with respect to the exploration of the potential use of joint-homing peptides for use in the investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (“Exclusive Option”) with respect to the subject technology. On July 6, 2021, the Company entered into a First Amendment Agreement (“First Amendment”) with UMB to extend the term of the original License Agreement by an additional six months such that the First Amendment was effective until February 25, 2022. On January 28, 2022, the Parties entered into a second amendment to the License Agreement to extend the term of the original license agreement until December 31, 2022. On June 22, 2022, the Parties entered into a third amendment to the License Agreement (“Third Amendment”). The Third Amendment expanded the scope of the license granted in the License Agreement to add additional patent rights with respect to an invention generally known as Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders. In consideration of the licenses granted under this Third Amendment, the Company agreed to pay a one-time, non-refundable fee of $2,500 which was recorded as research and development expense in the unaudited consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. On December 16, 2022, the Company and UMB entered into a fourth amendment to License Agreement (the “Fourth Amendment”) to extend the term of the License Agreement until March 31, 2023. In addition, the parties agreed in the Fourth Amendment to allow the Company to extend the term of the License Agreement to June 30, 2023 by paying UMB a fee of $1,000 on or before February 28, 2023. This fee was paid and the term of the License Agreement was extended to June 30, 2023. In February 2023, upon payment of the extension fee of $1,000, the Company recorded license fees of $1,000 which are included in research and development expenses on the accompanying unaudited consolidated statement of operations and comprehensive loss. On June 28, 2023, the Company and UMB entered into a fifth amendment to License Agreement (the “Fifth Amendment”) to extend the term of the License Agreement until September 30, 2023. The Company may at its option extend this Agreement until December 31, 2023, by providing written notice to University on or before August 31, 2023, and by paying an additional license fee of $2,500. This fee was paid and the term of the License Agreement was extended to December 31, 2023. In August 2023, upon payment of the extension fee of $2,500, the Company recorded license fees of $2,500 which are included in research and development expense on the accompanying unaudited consolidated statement of operations and comprehensive loss. As of December 31, 2023, the Company decided not to extend this License Agreement and will not continue to pursue this license.

Master License Agreement with the University of Maryland, Baltimore

As disclosed above, effective as of February 12, 2021, the Company and University of Maryland, Baltimore (“UMB”), entered into the Master License Agreement (“Master License Agreement”) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled, “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” and UMB’s confidential information to develop and perform certain licensed processes for the therapeutic treatment of neuroinflammatory disease.

The Master License Agreement will remain in effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the Master License Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.

-15-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

The Company may assign, sublicense, grant, or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company’s sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.

Pursuant to the Master License Agreement, the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company paid to UMB a license fee of $75,000, which was paid as follows: (a) $25,000 was due and paid within 30 days following the effective date; and (b) $50,000 was paid in February 2022. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The $75,000 license fee was recorded as a prepaid expense and is being amortized over the 15-year term. During the six months ended June 30, 2024 and 2023, the Company recognized license fees of $2,500 and $2,500, respectively, from the amortization of prepaid license fees, which is included in costs of revenues on the accompanying unaudited consolidated statements of operations. On June 30, 2024, prepaid expense and other current assets – current amounted to $5,000 and prepaid expense – non-current amounted to $53,125. On December 31, 2023, prepaid expense and other current assets – current amounted to $5,000 and prepaid expense – non-current amounted to $55,625 as reflected in the unaudited consolidated balance sheets.

Milestone	Payment
Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product	$	50,000
Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product	$	100,000
Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product	$	250,000
Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product	$	500,000
Achievement of First Commercial Sale of Licensed Product	$	1,000,000

Royalty Payments Terms:

(i)

3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and

(ii)

5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and

(iii)

minimum annual royalty payments, as follows:

Years	Minimum Annual Royalty
Prior to First Commercial Sale	$	N/A
Year of First Commercial Sale	$	N/A
First calendar year following the First Commercial Sale	$	25,000
Second calendar year following the First Commercial Sale	$	25,000
Third calendar year following the First Commercial Sale	$	100,000

On November 10, 2023, the Company entered into a Third Amendment to Master License Agreement (the “Third Amendment”) with UMB, pursuant to which the parties agreed to an amended and restated schedule of diligence milestones for the Master License Agreement.

-16-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

In April 2021, in connection with the Company’s Sublicense Agreement with Aikido Pharma Inc. (see below - Patent License Agreement with Aikido Pharma Inc.), the Company paid 25% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. During the six months ended June 30, 2024 and 2023, the Company recognized license fees of $419 and $419, respectively, from the amortization of the sublicense fee. On June 30, 2024, prepaid expense and other current assets – current amounted to $838 and prepaid expenses – non-current amounted to $8,939. On December 31, 2023, prepaid expense and other current assets – current amounted to $838 and prepaid expenses – non-current amounted to $9,358 as reflected in the unaudited consolidated balance sheets.

Exclusive License Agreement with the Trustees of Columbia University in the City of New York

On July 1, 2024 (, the Company entered into an exclusive license agreement (the “Columbia License Agreement”) with Columbia University (“Columbia”) with an effective date of June 28, 2024 (the “Effective Date”) and pursuant to which the Company has been granted exclusive rights to certain patents and technical information to develop, manufacture and commercialize Products (as defined in the Columbia License Agreement), including therapies for stress-induced affective disorders and other conditions. The term of the Columbia License Agreement shall commence on the Effective Date and shall continue on a country-by-country and product-by-product basis until the latest of: (a) the date of expiration of the last to expire of the issued Patents (as defined in the Columbia License Agreement), (b) 20 years after the first bona fide commercial sale of the Product in the country in question, or (c) expiration of any market exclusivity period granted by a regulatory agency for a Product in the country in question. Pursuant to the Columbia License Agreement, the Company agreed to pay Columbia:

(i)

an initial license fee of $50,000 due on the Effective Date and included in intangible assets and accounts payable on the accompanying unaudited consolidated balance sheet as of June 30, 2024.

(ii)

an annual license fee of $25,000 payable on the 1st and 2nd anniversary of the Effective Date and an annual license fee of $50,000 payable on the third and subsequent anniversary of the Effective Date.

(iii)

Royalties as follows:

(A)

Concerning sales of Products by the Company, its Designees, or their Affiliates in the Territory, a non-refundable and non-recoverable royalty of the following on a country-by-country and Product-by-Product basis:

(1)

4% of Net Sales of Patent Products; and

(2)

2% of Net Sales of Technology Products.

(B)

No later than 30 days following the second (2nd) anniversary of the first bona fide commercial sale of a Product by the Company, a Sublicensee, a Designee, or any of their Affiliates to a Third-Party customer, and the first business day of each January after that, the Company shall pay Columbia a non-refundable and non-recoverable minimum royalty payment in the amount of $500,000. The Company may credit each minimum royalty payment against earned royalties accrued during the same calendar year in which the minimum royalty payment is due and payable. To the extent minimum royalty payments exceed the earned royalties accrued during the same calendar year, the Company may not carry over this excess amount to any other year, either to decrease the earned royalties due in that year or to decrease the minimum royalty payments due in that year; and

(iv)

Trigger Event Fee: The Company shall pay Columbia a Trigger Event Fee within 30 days after the Initial Date or, if later, within 10 days following the date upon which the Trigger Event Fee. A Trigger Event means any Assignment of the Columbia License Agreement or Change of Control and a Trigger Event Fee shall mean an additional cash license fee equal to 5% of the Business Valuation, as defined in the agreement.

(v)

The Company shall reimburse Columbia for patent expenses as follows:

(i)

The Company shall reimburse Columbia for the actual fees, costs, and expenses Columbia has incurred before, on, and after the Effective Date in preparing, filing, prosecuting, and maintaining the Patents (and those patents and patent applications to which Patents claim priority) (collectively “Patent Expenses”). Patent Expenses include, without limitation, legal fees, the costs of any interference proceedings, oppositions, re-examinations, or any other ex parte or inter partes administrative proceeding before patent offices, taxes, annuities, issue fees, working fees, maintenance fees, and renewal charges, plus a five percent processing fee.

-17-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

(ii)

Unreimbursed Patent Expenses that Columbia incurred for legal activities occurring before September 30, 2021 are “Past Patent Expenses.”

(iii)

Columbia, using reasonable efforts, estimates that unreimbursed Patent Expenses for legal activities occurring before September 30, 2021 are $197,400 (“Estimated Past Patent Expenses”). The Company shall reimburse Columbia in full no later than thirty (30) days after the Effective Date. On June 28, 2024, the Company considered the Estimated Past Patents Expenses due of $197,400 as part of the cost of entering into the Columbia License Agreement license and accordingly, increased intangible assets and accounts payable by $197,400.

(iv)

The Company will pay any additional unreimbursed Past Patent Expenses within thirty (30) days after receiving an invoice from Columbia for the additional Past Patent Expenses.

(v)

The Company will reimburse Columbia for unreimbursed Patent Expenses incurred by Columbia after the Past Patent Expenses (“Ongoing Patent Expenses”) no later than thirty (30) days after receiving Columbia’s invoice.

(vi)

At Columbia’s election, Columbia may require advance payment of a reasonable estimate of Ongoing Patent Expenses (“Estimated Ongoing Patent Expenses”). Columbia shall give at least thirty (30) days’ notice to the Company before the date the advance payment is due, which payment Columbia may make due up to three months before the date Columbia has chosen for the legal work to be completed. Columbia may credit any unused balance towards future Patent Expenses, or upon the Company’s written request, Columbia shall return the unused balance to the Company. No later than thirty (30) days after receiving an invoice from Columbia for any Patent Expenses incurred over the reasonable estimate, the Company shall reimburse Columbia for the excess amount.

License Agreements between the Company and Customer

Customer Patent License Agreement with Aikido Pharma Inc.

On January 5, 2021, the Company and its subsidiary Silo Pharma, Inc., entered into a patent license agreement (“License Agreement”) (collectively, the “Licensor”) with Aikido Pharma Inc. (“Aikido” or the “Customer”), as amended on April 12, 2021, pursuant to which the Licensor granted Aikido an exclusive, worldwide (“Territory”), sublicensable, royalty-bearing license to certain intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused by cancer (“Field of Use”).

The License Agreement also provided that, if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (“Right”) to certain UMB patent rights in the field of neuroinflammatory diseases occurring in patients diagnosed with cancer (“Field”). Pursuant to the License Agreement, Aikido agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the Licensor 500 shares of Aikido’s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate of 625,000 shares of Aikido’s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement (“Amended License Agreement”) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted shares of Aikido’s common stock instead of the 500 shares of the Series M Convertible Preferred Stock.

Pursuant to the License Agreement, the Company is required to prepare, file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (“Patent Challenge”) against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause, and without incurring any additional penalty, (i) by providing at least 30 days’ prior written notice and paying the Company all amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January 5, 2021 which was recorded as deferred revenue to be recognized as revenues over 15 years, the estimated term of the UMB Master License Agreement.

-18-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Prior to the April 12, 2021, issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the estimated term of the UMB Master License. Accordingly, the Company recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized as revenues over the 15-year term.

During the six months ended June 30, 2024 and 2023, the Company recognized license fee revenues of $34,375 and $34,375, respectively. On June 30, 2024, deferred revenue – current portion amounted to $68,750 and deferred revenue – long-term portion amounted to $721,875. On December 31, 2023, deferred revenue – current portion amounted to $68,750 and deferred revenue – long-term portion amounted to $756,250 as reflected in the unaudited consolidated balance sheets.

The Right shall be, to the full extent permitted by and on terms and conditions required by UMB, for a term consistent with the term of patent and technology licenses that UMB normally grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed 110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly, on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive sublicense to its licensed patents under the Master License Agreement.

Customer Sublicense Agreement with Aikido Pharma Inc.

On April 6, 2021 (the “Sublicense Agreement Effective Date”), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and (ii) in connection therewith to (A) use an invention known as “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” which was sublicensed to the Company pursuant to the Master License Agreement and (B) practice certain patent rights (“Patent Rights”) for the therapeutic treatment of neuroinflammatory disease in cancer patients. “Licensed Products” means any product, service, or process, the development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent Rights.

Pursuant to the Sublicense Agreement, Aikido agreed to pay the Company (i) an upfront license fee of $50,000, (ii) the same sales-based royalty payments that the Company is subject to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii) 10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront license fee of $50,000 in April 2021. During the six months ended June 30, 2024 and 2023, the Company recognized revenue of $1,676 and $1,676, respectively. On June 30, 2024, deferred revenue – current portion amounted to $3,352 and deferred revenue – long-term portion amounted to $35,754, and on December 31, 2023, deferred revenue – current portion amounted to $3,352 and deferred revenue – long-term portion amounted to $37,430 as reflected in the unaudited consolidated balance sheets.

Sponsored Study and Research Agreements between the Company and Vendors

Investigator-Sponsored Study Agreement with University of Maryland, Baltimore

On January 5, 2021, the Company entered into an investigator-sponsored study agreement (“Sponsored Study Agreement”) with the University of Maryland, Baltimore. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (“MS”). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost under the Sponsored Study Agreement shall not exceed $81,474 which was payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. In 2021, the Company paid $40,737 and recorded research and development expense of $40,737. This project has been postponed until further notice and the second payment is not due.

-19-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Sponsored Research Agreement with The Regents of the University of California

On June 1, 2021 (the “Effective Date”), the Company entered into a sponsored research agreement (the “Sponsored Research Agreement”) with The Regents of the University of California, on behalf of its San Francisco Campus (“UCSF”) pursuant to which UCSF shall conduct a study to examine psilocybin’s effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson’s Disease, chronic pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over the two-year period. The Agreement was effective for a period of two years from the Effective Date, subject to renewal or earlier termination as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored Research Agreement, the Company paid to UCSF $181,710 and $100,570, respectively, which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. During the year ended December 31, 2023, the Company paid the remaining amount due of $60,570. During the six months ended June 30, 2024 and 2023, the Company recorded research and development expenses of $0 and $71,427, respectively, from the amortization of the prepaid research and development fees. On June 30, 2024 and December 31, 2023, there were no remaining prepaid research and development fees relating to this agreement.

Sponsored Research Agreement with University of Maryland, Baltimore

On July 6, 2021, the Company and University of Maryland, Baltimore (“UMB”) entered into a sponsored research agreement (“July 2021 Sponsored Research Agreement”) pursuant to which UMB shall evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either party upon 30 days’ prior written notice to the other party. In addition, if either party commits any material breach of or defaults with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within 10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. On June 7, 2022, the Company and UMB amended the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project work and budget. The amendment had no effect on the unaudited consolidated financial statements.

Pursuant to the terms of the July 2021 Sponsored Research Agreement, UMB granted the Company an option (the “Option”) to negotiate and obtain an exclusive license to any UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB’s rights in any Joint Arising IP (as defined in the July 2021 Sponsored Research Agreement) (collectively, the “UMB IP”). The Company may exercise the Option by giving UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement, the Company shall pay UMB the fees below:

	Payment
1	$	92,095	Paid upon execution of the July 2021 Sponsored Research Agreement
2	$	92,095	Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement
3	$	92,095	Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement

The Company paid the first payment of $92,095 on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $92,095. These payments were recorded to prepaid expense and other current assets – current to be amortized into research and development expense during the years ended December 31, 2022 and 2021. During the six months ended June 30, 2024 and 2023, there were no recorded research and development expenses from the amortization of these prepaid research and development fees and other expenses. On June 30, 2024 and December 31, 2023, the Company owed UMB $92,095 which was included in accounts payable on the accompanying unaudited consolidated balance sheets.

-20-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Sponsored Research Agreement with Columbia University

On October 1, 2021, the Company entered into a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets currently under development, including assets related to the potential treatment of patients suffering from Alzheimer’s disease. The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the date of the Company’s receipt of a final research report for each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the date of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 and the second payment of $430,825 in July 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. On October 13, 2022, the Company entered into an amendment to the Columbia Agreement (the “Columbia Amendment”), pursuant to which the parties agreed to extend the payment schedule, whereby the third payment of $430,825 was due in March 2023. In August 2023, the Company paid $100,000 of this balance and $330,825 of such payment remains unpaid as of June 30, 2024 and December 31, 2023, which is included in accounts payable on the accompanying unaudited consolidated balance sheet. The remaining payment of $143,607 is due upon completion.

During the six months ended June 30, 2024 and 2023, the Company recorded research and development expense of $0 and $215,412, respectively, from the amortization of the prepaid research and development fees. As of June 30, 2024, the Company estimates that this research project is approximately 90% complete.

Research Agreement with Reprocell

On October 25, 2022, (the “Effective Date”), the Company entered into a research agreement (the “Reprocell Research Agreement”) with Reprocell Europe Ltd. (“Reprocell”) pursuant to which Reprocell shall conduct a study to assess the binding of a peptide on healthy and rheumatoid arthritis synovial tissue. Pursuant to the Reprocell Research Agreement, the Company shall pay Reprocell a total fee of $41,306 to conduct the research over a three-month period. During the year ended December 31, 2022, pursuant to the Reprocell Research Agreement, the Company paid to Reprocell $21,172 which was recorded as prepaid expense and other current assets – current to be amortized over the three-month period. During the six months ended June 30, 2024 and 2023, the Company recorded research and development expense of $0 and $13,944 from the amortization of the prepaid research and development fees and the payment of other fees. As of June 30, 2024 and December 31, 2023, accounts payable and accrued expenses related to this research agreement were $0 and $5,891, respectively.

Research Agreements with Upperton Pharma Solutions

On February 28, 2023 and October 16, 2023, (the “Effective Dates”), the Company entered into research agreements (the “Upperton Research Agreements”) with Upperton Pharma Solutions (“Upperton”) pursuant to which Upperton shall conduct a study to support the development and feasibility of Prucalopride nasal solutions. Pursuant to the October 16, 2023 Upperton Research Agreement, the Company shall pay Upperton an aggregate total fee of approximately 216,210 British Pound (GBP) (approximately $272,620) to conduct the research, which will expensed over the research period. During the year ended December 31, 2023, pursuant to the Upperton Research Agreements, the Company paid Upperton $177,903. During the six months ended June 30, 2024 and 2023, the Company recorded research and development expense of $181,944 and $27,423, respectively, from the amortization of the prepaid research and development fees. As of June 30, 2024 and December 31, 2023, accounts payable and accrued expenses related to Upperton research agreements were $61,945 and $34,525, respectively.

Research Agreement with AmplifyBio

On October 16, 2023 and May 5, 2024, (the “Effective Dates”), the Company entered into research agreements (the “AmplifyBio Research Agreements”) with AmplifyBio, LLC. (“AmplifyBio”) pursuant to which AmplifyBio shall conduct a study in rates to investigate intranasal administration of a novel drug product. Pursuant to the AmplifyBio Research Agreements, the Company shall pay AmplifyBio a total fee of $958,700 to conduct the research. During the year ended December 31, 2023, pursuant to the October 16, 2023 AmplifyBio Research Agreement, the Company paid AmplifyBio $182,980 which was recorded as prepaid expense and other current assets – current, and was amortized into research and development expense during 2023. During the six months ended June 30, 2024 and 2023, pursuant to the AmplifyBio Research Agreements, the Company paid and recorded research and development expense of $119,340 and $0, respectively. As of June 30, 2024, $656,380 of research remains to be billed by AmplifyBio. As of June 30, 2024 and December 31, 2023, accounts payable related to this research agreement were $67,720 and $0, respectively.

-21-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

Research Agreement with Sever Pharma Solutions

On April 26, 2023 and June 11, 2024, (the “Effective Dates”), the Company entered into research agreements (the “Sever Pharma Research Agreements”) with Foster Delivery Science, Inc, dba as Sever Pharma Solutions (“Sever Pharma”) pursuant to which Sever Pharma shall conduct a study of pre-clinical extrusion of proof-of-concept of PLGA/Ketamine Implants and extrusion of ketamine loaded implants including analytical testing and sterilization. Pursuant to the Sever Pharma Research Agreements, the Company shall pay Sever Pharma a total fee of $654,510 to conduct the research plus the cost of change orders, as needed. During the six months ended June 30, 2024 and year ended December 31, 2023, the Company paid Sever Pharma $181,746 and $26,612, respectively. During the six months ended June 30, 2024 and 2023, pursuant to this agreement, the Company recorded research and development expense of $217,664 and $0, respectively. As of June 30, 2024, $452,241 of research remains to be billed by Sever Pharma pursuant to this agreement. As of June 30, 2024 and December 31, 2023, accounts payable related to this research agreement were $35,918 and $0, respectively.

During the six months ended June 30, 2024 and 2023, the Company entered into other research and development agreements. In connection with such agreements, the Company recorded research and development expenses of $18,472 and $32,849, respectively.

On June 30, 2024, future amounts due under sponsored study and research agreements between the Company and vendors is as follows:

Year ended June 30,	Amount
2025	$	1,878,928
Total	$	1,878,928

Joint Venture Agreement with Zylö Therapeutics, Inc.

On April 22, 2021 (“Effective Date”), the Company entered into a Joint Venture Agreement (“JV Agreement”) with Zylö Therapeutics, Inc. (“ZTI”) pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (“Joint Venture”), to, among other things, focus on the clinical development of ketamine using ZTI’s Z-pod™ technology (“Venture”). Pursuant to the JV Agreement, the Company shall act as the manager (“Manager”) of the Joint Venture. The Joint Venture shall terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint Venture at any time.

Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. As of June 30, 2024 and December 31, 2023 and as of the current date of this report, the joint venture entity has not been formed yet.

Furthermore, pursuant to the terms of the JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the “License Agreement”) with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented technology (the “Patented Technology”) licensed to ZTI pursuant to the License Agreement is needed to advance the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI’s Z-pod™ technology on the same terms and conditions set forth in the JV Agreement, which option expired 24 months after the JV Effective Date.

Amended Service Agreement

On September 10, 2021 (“Effective Date”), the Company entered into an Amendment Agreement (“Amended Service Agreement”) to a certain service agreement dated on September 8, 2020 with the University of Texas (“University”) at Austin whereby the University will provide advisory service and assist the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000 per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined in the agreement. During the six months ended June 30, 2024 and 2023, the Company paid $10,000 and $15,000, respectively, related to this agreement which in included in professional fees on the accompanying unaudited consolidated statements of operations.

-22-

SILO PHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024

(UNAUDITED)

NOTE 9 – SUBSEQUENT EVENTS

Exclusive License Agreement with the Trustees of Columbia University in the City of New York

See “Note 8—Commitments and Contingencies-- License Agreements between the Company and Vendors--Exclusive License Agreement with the Trustees of Columbia University in the City of New York” above for a discussion of the Company’s license agreement with Columbia University.

Sale of Common Stock and Warrants

On July 18, 2024, the Company entered into a securities purchase agreement (the “July 2024 Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 763,638 shares (the “Shares”) of common stock of the Company (the “Common Stock”), at a purchase price of $2.75 per share of Common Stock (the “Offering”). The shares of Common Stock were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-276658), which was declared effective by the Securities and Exchange Commission on January 30, 2024.

Concurrently with the sale of Common Stock, pursuant to the July 2024 Purchase Agreement in a private placement, for each share of Common Stock purchased by the investors, such investors received from the Company an unregistered warrant (the “July 2024 Common Warrants”) to purchase one share of common stock for an aggregate of 763,638 July 2024 Common Warrants. The July 2024 Warrants have an exercise price of $2.75 per share and are exercisable immediately upon issuance for a five-year period.

The closing of the sales of these securities under the July 2024 Purchase Agreement took place on July 22, 2024. The gross proceeds from the offering were $2,100,005, prior to deducting placement agent’s fees and other offering expenses payable by the Company, and the Company received net proceeds of $1,780,555, net of Underwriters discounts and offering costs of $269,450 and legal fees of $50,000. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

On April 23, 2024, the Company entered into an engagement agreement with H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as placement agent on a reasonable “best efforts” basis in connection with the Offering. The Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.5% of the gross proceeds from the sale of securities in the Offering and a management fee equal to 1.0% of the gross proceeds raised in the Offering. The Company also agreed to issue the Placement Agent (or its designees) a warrant (the “Placement Agent Warrant”) to purchase up to 7.5% of the aggregate number of shares of Common Stock sold in the offering. In connection with the July 18, 2024 Purchase Agreement, the Company paid the Placement Agent a cash fee and management fee of $178,500 and the Placement Agent received Placement Agent Warrants to purchase up to 57,273 shares of Common Stock, at an exercise price equal to 125.0% of the offering price per share of Common Stock, or $3.4375 per share. The Placement Agent Warrants are exercisable immediately upon issuance for a period of five years following the commencement of the sales pursuant to the Offering. In addition, the Company paid to pay the Placement Agent $25,000 for non-accountable expenses, $50,000 for legal expenses and other out-of-pocket expenses and $15,950 for clearing fees.

Pursuant to the terms of the Purchase Agreement and subject to certain exceptions as set forth in the Purchase Agreement, from the date of the Purchase Agreement until fifteen days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. In addition, until the one year from the Closing Date, the Company is prohibited from entering into a Variable Rate Transaction (as defined in the Purchase Agreement), subject to certain limited exceptions.

Each of our executive officers and directors have agreed, subject to certain exceptions, not to dispose of or hedge any shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock during the period from the date of the lock-up agreement continuing through the fifteen (15) days after the closing of this offering.

The Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale of the Common Warrant Shares (the “Resale Registration Statement”) within 45 calendar days of the date of the Purchase Agreement (the “Filing Date”), and to use commercially reasonable efforts to cause the Resale Registration Statement to be declared effective by the SEC within 75 calendar days following the date of the Filing Date and to keep the Resale Registration Statement effective at all times until the Holders no longer own any Common Warrants or Common Warrant Shares.

-23-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and related notes for the year ended December 31, 2023 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this Quarterly Report on Form 10-Q, including those factors set forth in the section entitled “Cautionary Note Regarding Forward-Looking Statements and Industry Data” and in the section entitled “Risk Factors” in Part II, Item 1A.

Overview

We are a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Company’s lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting the central nervous system with initial research indication in multiple sclerosis (MS).

Rare Disease Therapeutics

We seek to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, ketamine, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. We are focused on developing traditional therapeutics and psychedelic medicine. The company concentrates on the development and commercialization of therapies for unmet needs from indications such as depression, post-traumatic stress disorder (“PTSD”), and other rare neurological disorders. Our mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.

Psilocybin is considered a serotonergic hallucinogen and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising, and we believe there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders. While classified as a Schedule I substance under the Controlled Substances Act (“CSA”), there is an accumulating body of evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug Administration (“FDA”) and U.S. Drug Enforcement Agency (“DEA”) have permitted the use of psilocybin in clinical studies for the treatment of a range of psychiatric conditions.

The potential of psilocybin therapy in mental health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated and may have the potential to treat depression when administered with psychological support.

We have engaged in discussions with a number of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board that is intended to help advise management regarding potential acquisition and development of products.

In addition, as more fully described below, we have entered into a license agreement with the University of Maryland, Baltimore, and developing a Ketamine polymer implant. In addition, we have recently entered into a sponsored research agreement with Columbia University pursuant to which we have been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.

We plan to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this new line of business.

-24-

Product Candidates

We are currently focusing on four product candidates: (i) SPC-15 for treatment of depression disorders; (ii) SP-26 for treatments of chronic pain; (iii)SPC-14 for the treatment of Alzheimer’s disease and (iv) SPU-16 for the treatment of CNS disorders with an initial indication for multiple sclerosis.

SPC-15

SPC-15 is a targeted prophylactic therapeutic composition for the treatment and prevention for stress-induced affective disorders including PTSD. The treatment predicts levels of severity or progression of such disorders and their metabolomic biomarkers’ response to pharmacological treatments. We intend to develop SPC-15 under the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (“FDCA”) was enacted to enable sponsors to seek New Drug Application (“NDA”) approval for novel repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.

On November 15, 2023, the Company entered an exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, as the delivery mechanism for SPC-15, which agreement has an effective date of October 31, 2023. Preclinical and formulation studies were completed in the first half of 2024 and on June 4, 2024 the Company submitted a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the U.S. Food and Drug Administration (FDA) for SPC-15, Silo’s intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder.

SP-26

In March 2023, the Company filed a provisional patent application with the USPTO to use SP-26 for treatment of chronic pain, including fibromyalgia. Fibromyalgia is a chronic condition causing pain to the connective tissues through the body including muscles, ligaments, and tendons. Musculoskeletal pain is often accompanied by sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. Fibromyalgia affects about 4 million American adults, or about 2% of the adult population.

We intend to develop SP-26 following the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the FDCA was enacted to enable sponsors to seek NDA approval for novel repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.

SPC-14

On October 1, 2021, the Company entered into a sponsored research agreement with Columbia University (“Columbia”) pursuant to which Columbia shall conduct two different studies related to the use of SPC-14 for the treatment of Alzheimer’s. See “Investigator-Sponsored Study Agreements between the Company and Vendors---Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer’s and Depression Disorders.” for additional details. In addition, Company has been granted an option to license certain assets currently under development, including SPC-14 for the treatment of Alzheimer’s disease. The Company exercised its option for an exclusive license agreement for SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD pursuant to which the Company was granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide on July 1, 2024. See “----License Agreements between the Company and Vendor—Exclusive License Agreement with Columbia University.”.

-25-

SPC-14 is a novel drug combining two approved therapeutics, so we intend to develop SPC-14 following the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of the FDCA was enacted to enable sponsors to seek NDA approval for novel repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.

On October 13, 2022, the Company extended the term of the sponsored research agreement with Columbia to conduct further research studies into the mechanism of action of SPC-14 in the treatment of Alzheimer’s disease. We expect the results from further preclinical studies in 2024.

SPU-16

SPU-16 is a novel peptide homing specifically to inflamed CNS areas. It may be used to diagnose neuroinflammation in patients, and targeted delivery of drugs into the spinal cord. The initial indication is for multiple sclerosis (MS). The peptides have been tested in the EAE mouse model of human MS, where they show homing specifically to inflamed CNS areas.

Product Development Pipeline

The following table summarizes our product development pipeline.

License Agreements between the Company and Vendor

Vendor License Agreement with the University of Maryland, Baltimore for CNS Homing Peptide

On February 12, 2021, we entered into a Master License Agreement (the “UMB License Agreement”) with the University of Maryland, Baltimore (“UMB”) pursuant to which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” (the “Invention”) and UMB’s confidential information to develop and perform certain licensed processes for the therapeutic treatment of neuroinflammatory disease. The term of the License Agreement shall commence on the UMB Effective Date and shall continue until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product in such country and (ii) the date of expiration of the last to expire claim of the Patent Rights (as defined in the UMB License Agreement) covering such Licensed Product in such country, or (iii) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, unless terminated earlier pursuant to the terms of the agreement. Pursuant to the UMB License Agreement, we agreed to pay UMB (i) a license fee of $75,000, (ii) certain event-based milestone payments, (iii) royalty payments, depending on net revenues, (iv) minimum royalty payments, and (v) a tiered percentage of sublicense income. The UMB License Agreement will remain in effect until the later of: (a) the last patent covered under the UMB License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) ten years after the first commercial sale of a licensed product in that country, unless earlier terminated in accordance with the provisions of the UMB License Agreement. The term of the UMB License Agreement shall expire 15 years after the effective date in which (a) there were never any patent rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was never a first commercial sale of a licensed product.

As described below, the Company has entered into an investigator sponsored research agreement with UMB related to a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of Multiple Sclerosis.

-26-

Commercial Evaluation License and Option Agreement with UMB for Joint Homing Peptide

Effective as of February 26, 2021, the Company, through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (“UMB”), entered into a commercial evaluation license and option agreement (“License Agreement”), which granted the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (“Exclusive Option”) with respect to the subject technology. The License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty days by giving a written notice.

On July 6, 2021, the Company entered into a First Amendment Agreement (“Amended License Agreement”) with UMB to extend the term of the original License Agreement by an additional six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021 pursuant to the License Agreement, which was expensed, since the Company could not conclude that such costs would be recoverable for this early-stage venture.

On January 28, 2022, the Company and UMB entered into a second amendment to the License Agreement dated February 26, 2021 (“Second Amendment”). The Second Amendment extended the term of the License Agreement until December 31, 2022. However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first.

On June 22, 2022, the Company and UMB entered into a third amendment to the License Agreement dated February 26, 2021 under which UMB agreed, to expand the scope of the license granted in the CELA to add additional Patent Rights with respect to an invention generally known as “Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders.” On December 16, 2022, the Company and UMB entered into a fourth amendment to License Agreement (the “Fourth Amendment”) dated February 26, 2021 to extend the term of the License Agreement until March 31, 2023. In addition, the parties agreed in the Fourth Amendment to allow the Company to extend the term of the License Agreement to June 30, 2023 by paying UMB a fee of $1,000 on or before February 28, 2023. This fee was paid and thus the term of the License Agreement was extended to June 30, 2023. We let this license expire by its terms on December 31, 2023.

Exclusive License Agreement with the Trustees of Columbia University in the City of New York

On July 1, 2024, the Company entered into an exclusive license agreement (the “Columbia License Agreement”) with Columbia University (“Columbia”) with an effective date of June 28, 2024 (the “Effective Date”) and pursuant to which the Company has been granted exclusive rights to certain patents and technical information to develop, manufacture and commercialize Products (as defined in the Columbia License Agreement), including therapies for stress-induced affective disorders and other conditions. The term of the Columbia License Agreement shall commence on the Effective Date and shall continue on a country-by-country and product-by-product basis until the latest of: (a) the date of expiration of the last to expire of the issued Patents (as defined in the Columbia License Agreement), (b) 20 years after the first bona fide commercial sale of the Product in the country in question, or (c) expiration of any market exclusivity period granted by a regulatory agency for a Product in the country in question

Joint Venture Agreement with Zylö Therapeutics, Inc. for Z-pod™ Technology

On April 22, 2021, the Company entered into a Joint Venture Agreement with Zylö Therapeutics, Inc. (“ZTI”) pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC, to, among other things, focus on the clinical development of ketamine using ZTI’s Z-pod™ technology. Pursuant to the Joint Venture Agreement, the Company shall act as the manager of the Joint Venture. The Venture shall terminate if the development program does not meet certain specifications and milestones as set forth in the Joint Venture Agreement within 30 days of the date set forth in the Joint Venture Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Venture at any time.

Pursuant to the terms of the Joint Venture Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the Joint Venture Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. As of June 30, 2024 and as of the current date of this Annual Report, the joint venture entity has not been formed yet.

-27-

On November 15, 2023, we entered into an Exclusive License Agreement (the “Medspray License Agreement”) with Medspray Pharma BV (“Medspray”) pursuant to which Medspray granted us an exclusive, non-revocable, worldwide royalty bearing license for Medspray’s proprietary patented soft mist nasal spray technology for marketing, promotion, sale and distribution of the products licensed by Medspray to us under the Medspray License Agreement. The Medspray License Agreement has an effective date of October 31, 2023 and expires on the earlier of (i) termination of the Medspray License Agreement or expiry of all Medspray license rights in the United States, Germany, United Kingdom, Spain, Italy and France. In consideration of the exclusive rights granted by Medspray to us, we agreed to pay Medspray a royalty on a quarterly basis equal to 5% of net sales. The term of the agreement commences on the effective date and continues until the earlier of (i) expiration of the last to expire of Medspray’s patent rights or (ii) December 31, 2023 (the “Initial Term”) at which time, the Medspray License Agreement will automatically renew for a successive period of three (3) years, unless terminated by either party upon one year prior written notice prior to the end of any term; provided, however, the Medspray may terminate the Medspray License Agreement immediately if fail to have any licensed product under the Medspray License Agreement registered with the FDA or EMA by July 1, 2028 or has filed to reach the point of first sale of any licensed product under the Medspray License Agreement by July 1, 2028.

Select Investigator-Sponsored Study Agreements between the Company and Vendors

Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer’s and Depression Disorders

On October 1, 2021, the Company entered into a sponsored research agreement with Columbia University (“Columbia”) pursuant to which Columbia shall conduct two different studies related to all uses of Ketamine or its metabolites in combination with Prucalopride, one of which is related to Alzheimer’s and the other of which is related to Depression, PTSD and Stress Projects. In addition, Company has been granted an option to license certain assets currently under development, including Alzheimer’s disease. The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the date of the Company’s receipt of a final research report for each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the option. The Company exercised its option for an exclusive license agreement for SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD pursuant to which the Company was granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. See “---License Agreements between the Company and Vendor—Exclusive License Agreement with Columbia University.”. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to posttraumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. On October 13, 2022, the Company entered into an amendment of the sponsored research agreement pursuant to which the parties agreed to extend the payment schedule until March 31, 2024. The Company paid the first payment of $430,825 in November 2021 and the second payment of $430,825 in July 2022.

-28-

Sponsored Research Agreement with University of Maryland, Baltimore for the Study of Targeted liposomal drug delivery for rheumatoid arthritis

On July 6, 2021, we entered into a sponsored research agreement (the “July 2021 Sponsored Research Agreement”) with UMB pursuant to which UMB shall evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research pursuant to the July 2021 Sponsored Research Agreement commenced on September 1, 2021 and will continue until the substantial completion thereof, subject to renewal upon written consent of the parties with a project timeline of twelve months. The July 2021 Sponsored Research Agreement may be terminated by either party upon 30 days’ prior written notice to the other party. In addition, if either party commits any material breach of or defaults with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within 10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for any reason other than an uncured material breach by UMB, we shall relinquish any and all rights it may have in the Results (as defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated early, we, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. Pursuant to the terms of the July 2021 Sponsored Research Agreement, UMB granted us an option (the “Option”) to negotiate and obtain an exclusive license to any UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB’s rights in any Joint Arising IP (as defined in the July 2021 Sponsored Research Agreement) (collectively, the “UMB IP”). We may exercise the Option by giving UMB written notice within 60 days after it receives notice from UMB of the UMB IP. We shall pay total fees of $276,285 as set forth in the July 2021 Sponsored Research Agreement. The Company paid the first payment of $92,095 on September 1, 2021 and on August 31, 2022, the Company paid the second payment of $92,095.

Sponsored Research Agreement with The Regents of the University of California for the Effect of Psilocybin on Inflammation in the Blood

On June 1, 2021, the Company entered into a sponsored research agreement (“Sponsored Research Agreement”) with The Regents of the University of California, on behalf of its San Francisco Campus (“UCSF”) pursuant to which UCSF shall conduct a study to examine psilocybin’s effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson’s Disease, chronic pain, and bipolar disorder. The purpose of this is to show what effect psilocybin has on inflammation in the blood. The Company believe that this study will help support the UMB homing peptide study. Pursuant to the Agreement, we shall pay UCSF a total fee of $342,850 to conduct the research over the two-year period. The Agreement shall be effective for a period of two years from the effective date, subject to renewal or earlier termination as set forth in the Sponsored Research Agreement. During the years ended December 31, 2022 and 2021, pursuant to the Sponsored Research Agreement, the Company paid to UCSF $181,710 and $100,570, respectively. We have notified UCSF we do not plan to continue this study.

Investigator-Sponsored Study Agreement with UMB for CNS Homing Peptide

On January 5, 2021, we entered into an investigator-sponsored study agreement with UMB. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of Multiple Sclerosis (“MS”). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the central nervous system and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and progression of Experimental Autoimmune Encephalomyelitis. Pursuant to the agreement, the research commenced on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost under the investigator-sponsored study agreement shall not exceed $81,474. which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021. This project has been postponed until further notice and the second payment is not due.

Stock Repurchase Plan

On January 26, 2023, the Company’s Board of Directors authorized a stock repurchase plan to repurchase up to $1,000,000 of our issued and outstanding common stock, from time to time, with such program to be in place until December 31, 2023. On January 9, 2024, the Board of Directors of the Company approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company’s common stock until March 31, 2024 and on April 4, 2024, the stock Repurchase Plan was extended to April 30, 2024. During the year ended December 31, 2023, the Company purchased 252,855 shares of common stock for a cost of $471,121, which is reflected in treasury stock on the accompanying unaudited consolidated balance sheet During the six months ended June 30, 2024, the Company purchased 102,855 shares of common stock for a cost of $173,113. As of June 30, 2024, the Company had repurchased an aggregate of 355,710 shares of its common stock for a total cost of $644,234 pursuant to its Stock Repurchase Program.

-29-

Short-Term Investments

Our portfolio of short-term investments consists of marketable debt securities which are comprised solely of that are all highly rated U.S. government securities with maturities of more than three months, but less than one year. We classify these as available-for-sale at purchase date and will reevaluate such designation at each period end date. We may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the unaudited consolidated balance sheet and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive gain and as a component of the unaudited consolidated statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income (expense), net in the unaudited consolidated statements of operations.

On June 30, 2024 and December 31, 2023, short-term investments, at fair value, amounted to $3,102,240 and $4,140,880, respectively.

Recent Developments

July 2024 Registered Direct Offering and Concurrent Private Placement

On July 18, 2024, we entered into a securities purchase agreement (the “July 2024 Purchase Agreement”) with certain institutional investors, pursuant to which we agreed to sell 763,638 shares (the “July 2024 Shares”) of our common stock, at a purchase price of $2.75 per share (the “July 2024 Offering”) for gross proceeds of approximately $2.1 million, prior to deducting placement agent’s fees and other offering expenses payable by us. We intend to use the net proceeds from the offering for working capital and other general corporate purposes. The shares were offered pursuant to our shelf registration statement on Form S-3 (File No. 333-276658), which was declared effective by the Securities Exchange Commission on January 30, 2024.

Concurrently with the sale of July 2024 Shares pursuant to the July 2024 Purchase Agreement in a private placement, for each share of Common Stock purchased by the investors, such investors received an unregistered warrant (the “July 2024 Investor Warrant”) to purchase one share of Common Stock, or 763,638 shares in the aggregate (the “July 2024 Investor Warrant Shares”). The July 2024 Investor Warrants have an exercise price of $2.75 per share, and are exercisable immediately upon issuance for a five-year period.

The closing of the sales of these securities under the Purchase Agreement took place on July 22, 2024.

On April 23, 2024, we entered into an engagement agreement with H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as placement agent on a reasonable “best efforts” basis in connection with the July 2024 Offering. We agreed to pay the Placement Agent an aggregate cash fee equal to 7.5% of the gross proceeds from the sale of securities in the Offering and a management fee equal to 1.0% of the gross proceeds raised in the Offering. We issued the Placement Agent’s designees warrants (the “July 2024 Placement Agent Warrants”) to purchase up to 7.5% of the aggregate number of July 2024 Shares, or warrants to purchase up to 57,273 shares of Common Stock, at an exercise price equal to 125.0% of the offering price per share of Common Stock, or $3.4375 per share. The July 2024 Placement Agent Warrants are exercisable immediately upon issuance for a period of five years following the commencement of the sales pursuant to the July 2024 Offering.

Exclusive License Agreement with Columbia University

On July 1, 2024, we entered into an Exclusive License Agreement with Columbia University with an effective date of June 28, 2024 under which we were granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. See “----License Agreements between the Company and Vendor—Exclusive License Agreement with Columbia University.”

Pre-IND Submission

On June 4, 2024, we submitted a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the U.S. Food and Drug Administration (FDA) for SPC-15, Silo’s intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder.

-30-

June 2024 Registered Direct Offering and Concurrent Private Placement

On June 4, 2024, we entered into a securities purchase agreement (the “June 2024 Purchase Agreement”) with certain institutional investors, pursuant to which we agreed to sell to such investors 883,395 shares (the “June 2024 Shares”) of Common Stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 34,037 shares of Common Stock (the “June 2024 Pre-Funded Warrant Shares”), having an exercise price of $0.0001 per share, at a purchase price of $2.18 per share of Common Stock and a purchase price of $2.1799 per Pre-Funded Warrant (the “June 2024 Offering”). The shares of Common Stock and Pre-Funded Warrants (and shares of common stock underlying the Pre-Funded Warrants) were offered by us pursuant to its shelf registration statement on Form S-3 (File No. 333-276658), which was declared effective by the Securities and Exchange Commission on January 30, 2024.

Concurrently with the sale of June 2024 Shares and/or the Pre-Funded Warrants, pursuant to the June 2024 Purchase Agreement in a private placement, for each share of Common Stock and/or Pre-Funded Warrant purchased by the investors, such investors received an unregistered warrant (the “June 2024 Investor Warrant”) to purchase one share of Common Stock, or 917,432 shares of Common Stock in the aggregate (the “June 2024 Investor Warrant Shares”). The warrants have an exercise price of $2.06 per share and are exercisable immediately upon issuance for a five-year period.

The closing of the sales of these securities under the June 2024 Purchase Agreement took place on June 6, 2024. The gross proceeds from the offering were approximately $2 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company. We intend to use the net proceeds from the offering for working capital and other general corporate purposes.

On April 23, 2024, we entered into an engagement agreement with H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as placement agent on a reasonable “best efforts” basis in connection with the Offering. We agreed to pay the Placement Agent an aggregate cash fee equal to 7.5% of the gross proceeds from the sale of securities in the Offering and a management fee equal to 1.0% of the gross proceeds raised in the Offering. We also issued the Placement Agent’s designees warrants (the “June 2024 Placement Agent Warrants”) to purchase up to 7.5% of the aggregate number of shares of Common Stock and/or Pre-Funded Warrants sold in the offering, or warrants to purchase up to 68,807 shares of Common Stock, at an exercise price equal to 125.0% of the offering price per share of Common Stock, or $2.725 per share. The June 2024 Placement Agent Warrants are exercisable immediately upon issuance for a period of five years following the commencement of the sales pursuant to the June 2024 Offering.

Results of Operations

Comparison of Our Results of Operations for the Three and Six Months Ended June 30, 2024 and 2023

The following table summarizes the results of operations for the three and six months ended June 30, 2024 and 2023 and were based primarily on the comparative unaudited consolidated financial statements, footnotes and related information for the periods identified and should be read in conjunction with the unaudited consolidated financial statements and the notes to those statements that are included elsewhere in this report.

	For the Three Months						For the Six Months
	Ended June 30,						Ended June 30,
	2024			2023			2024			2023
License fee revenues	$	18,025		$	18,025		$	36,051		$	36,051
Cost of revenues		(1,459	)		(1,459	)		(2,919	)		(2,919	)
Gross profit		16,566			16,566			33,132			33,132
Operating expenses		(1,019,340	)		(1,131,551	)		(1,915,419	)		(1,951,602	)
Loss from operations		(1,002,774	)		(1,114,985	)		(1,882,287	)		(1,918,470	)
Other income (expense), net		70,995			102,034			148,841			(877	)
Net loss	$	(931,779	)	$	(1,012,951	)	$	(1,733,446	)	$	(1,919,347	)

Revenues

During the three and six months ended June 30, 2024 and 2023, we generated minimal revenues from operations. For the three months ended June 30, 2024 and 2023, revenues amounted to $18,025 and $18,025, respectively. For the six months ended June 30, 2024 and 2023, revenues amounted to $36,051 and $36,051, respectively. Such revenues are related to the Aikido License and Sublicense Agreement and are recognized over the term of the related license agreement.

Cost of Revenues

During the three months ended June 30, 2024 and 2023, cost of revenues amounted to $1,459 and $1,459, respectively. During the six months ended June 30, 2024 and 2023, cost of revenues amounted to $2,919 and $2,919, respectively. Cost of revenues consists of license fees related to the UMB License and Sublicense Agreement, which are being amortized into cost of revenues over the terms of their respective agreement.

-31-

Operating Expenses

For the three and six months ended June 30, 2024 and 2023, total operating expenses consisted of the following:

	For the Three Months				For the Six Months
	Ended June 30,				Ended June 30,
	2024		2023		2024		2023
Compensation expense	$	168,381	$	169,186	$	341,727	$	331,443
Professional fees		386,465		570,295		641,067		935,565
Research and development		392,824		130,719		774,889		333,632
Insurance expense		21,101		22,251		42,805		46,896
Selling, general and administrative expenses		50,569		239,100		114,931		304,066
Total operating expenses	$	1,019,340	$	1,131,551	$	1,915,419	$	1,951,602

●

Compensation Expense:

For the three months ended June 30, 2024 and 2023, compensation expense amounted to $168,381 and $169,186, respectively, a decrease of $805, or 0.5%. This decrease resulted from a decrease in stock-based compensation of $4,237, offset by an increase in payroll expense and related benefits of $3,432.

For the six months ended June 30, 2024 and 2023, compensation expense was $341,727 and $331,443, respectively, an increase of $10,284, or 3.1%. This increase resulted from an increase in payroll expense and related benefits of $18,758, offset by a decrease in stock-based compensation of $8,474.

●

Professional Fees:

For the three months ended June 30, 2024 and 2023, professional fees were $386,465 and $570,295 and, respectively, a decrease of $183,830, or 32.2%. The decrease was primarily attributable to a decrease in legal fees of $173,699, a decrease in other consulting fees of $142,279, and a decrease in stock-based consulting fees of $33,775 related to the amortization of prepaid expense on previously issued shares to consultants for business advisory and strategic planning services, offset by an increase in investor relations of $159,500, and an increase in accounting and auditing fees of $6,423. During the three months ended June 30, 2024, we reimbursed Columbia University $6,673 related to patent related legal fees incurred by them on our behalf.

For the six months ended June 30, 2024 and 2023, professional fees were $641,067 and $935,565 and, respectively, a decrease of $294,498, or 31.5%. The decrease was primarily attributable to a decrease in other consulting fees of $244,923, a decrease in legal fees of $147,791, and a decrease in stock-based consulting fees of $67,550 related to the amortization of prepaid expense on previously issued shares to consultants for business advisory and strategic planning services, offset by an increase in investor relations of $156,612, and an increase in accounting and auditing fees of $9,154. During the six months ended June 30, 2024, we reimbursed Columbia University $18,140 related to patent related legal fees incurred by them on our behalf.

●

Research and Development:

For the three months ended June 30, 2024 and 2023, we incurred research and development expense of $392,824 and $130,719, respectively, an increase of $262,105, or 200.5%. For the six months ended June 30, 2024 and 2023, we incurred research and development expense of $774,889 and $333,632, respectively, an increase of $441,257, or 132.3%.

The increase was a result of an increase in research and development costs in connection with the Investigator-sponsored Study Agreement with UCSF, UMB, Columbia University, and other parties.

●

Insurance Expense:

For the three months ended June 30, 2024 and 2023, insurance expense was $21,101 and $22,251, respectively, a decrease of $1,151, or 5.2%. For the six months ended June 30, 2024 and 2023, insurance expense was $42,805 and $46,896, respectively, a decrease of $4,092, or 8.7%.

This decrease was a result of decrease in the cost of renewal of the D&O insurance policy.

-32-

●

Selling, General and Administrative Expenses:

Selling, general and administrative expenses include advertising and promotion, patent related expenses, public company expenses, custodian fees, bank service charges, travel, and other office expenses.

For the three months ended June 30, 2024 and 2023, selling, general and administrative expenses were $50,569 and $239,100, respectively, a decrease of $188,528 or 78.8%. The decrease was primarily attributed to a decrease in Delaware franchise taxes of $200,000 resulting from a reincorporation of the Company in Nevada, offset by a net increase in other general and administrative expenses of $11,401.

For the six months ended June 30, 2024 and 2023, selling, general and administrative expenses were $114,931 and $304,066, respectively, a decrease of $189,135 or 62.2%. The decrease was primarily attributed to a decrease in Delaware franchise taxes of $214,967 resulting from a reincorporation of the Company in Nevada, offset by a net increase in other general and administrative expenses of $14,363.

Loss from Operations

For the three months ended June 30, 2024 and 2023, loss from continuing operations amounted to $1,002,774 and $1,114,985 respectively, a decrease of $112,211, or 10.1%. For the six months ended June 30, 2024 and 2023, loss from continuing operations amounted to $1,882,287 and $1,918,470, respectively, a decrease of $36,183, or 1.9%.

The decrease was primarily a result of the changes in operating expenses discussed above.

Other Income (Expenses), net

For the three months ended June 30, 2024 and 2023, other income, net amounted to $70,995 and $102,034, respectively, a decrease of $31,039, or 30.4%. The decrease in other income, net was primarily due to a decrease in interest and dividend income of $32,541, and an increase in foreign currency transaction loss of $2,929, offset by a decrease in net unrealized loss on equity investment of $3,508, and a decrease in net realized loss on short-term investments of $920.

For the six months ended June 30, 2024 and 2023, other income (expense), net amounted to $148,841 and $(877), respectively, a positive change of $149,718, or 17,078.2%. The positive change in other income (expenses), net was primarily due to a decrease in penalty expense of $166,034 which was incurred due to the early termination of a certificate of deposit, a decrease in net unrealized loss on equity investment of $3,118, a decrease in net realized loss on short-term investments of $1,154, offset by an increase in foreign currency transaction loss of $11,624, a decrease in interest and dividend income of $8,753, and an increase in interest expense of $211.

Net Loss

For the three months ended June 30, 2024, net loss amounted to $931,779 or $0.31 loss per common share (basic and diluted), as compared to net loss of $1,012,951, or $0.32 loss per common share (basic and diluted) for the three months ended June 30, 2023, a decrease of $81,172, or 8.0%. For the six months ended June 30, 2024, net loss amounted to $1,733,446 or $0.59 loss per common share (basic and diluted), as compared to net loss of $1,919,347, or $0.61 loss per common share (basic and diluted) for the six months ended June 30, 2023, a decrease of $185,901, or 9.7%.

The changes were primarily a result of the changes discussed above.

Liquidity and Capital Resources

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. We had working capital of $6,405,949, $3,102,240 in short-term investments, and $4,506,300 in cash and cash equivalents as of June 30, 2024, and working capital of $6,905,568, $4,140,880 in short-term investments and $3,524,308 in cash and cash equivalents as of December 31, 2023, respectively.

	June 30, 2024			December 31, 2023			Working Capital Change			Percentage Change
Working capital:
Total current assets	$	7,728,828		$	7,681,158		$	47,670			1	%
Total current liabilities		(1,322,879	)		(775,590	)		(547,289	)		(71	)%
Working capital:	$	6,405,949		$	6,905,568		$	(499,619	)		(7	)%

The decrease in working capital of $499,619 was primarily attributable to an increase in current liabilities of $547,289 due to an increase in accounts payable, offset by a net increase in current assets of $47,670.

-33-

Cash Flows

A summary of cash flow activities is summarized as follows:

	Six Months Ended June 30,
	2024			2023
Net cash used in operating activities	$	(1,569,982	)	$	(1,242,654	)
Net cash provided by (used in) investing activities		1,051,868			(9,834,589	)
Net cash provided by (used in) financing activities		1,500,106			(130,959	)
Net increase (decrease) in cash and cash equivalents	$	981,992		$	(11,208,202	)

Net Cash Used in Operating Activities

Net cash used in operating activities for the six months ended June 30, 2024 and 2023 were $1,569,982 and $1,242,654, respectively, an increase of $327,328, or 26.3%.

●

Net cash used in operating activities for the six months ended June 30, 2024 primarily reflected a net loss of $1,733,446, adjusted for the add-back of non-cash items such as net realized gain on short-term investments of $1,025, and changes in operating asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $101,399, an increase in accounts payable and accrued expenses of $299,889, and a decrease in deferred revenue of $36,051.

●

Net cash used in operating activities for the six months ended June 30, 2023 primarily reflected a net loss of $1,919,347, adjusted for the add-back of non-cash items such as net realized and unrealized loss on equity investments of $5,297, stock-based compensation of $8,474, and amortization of prepaid stock-based professional fees of $67,550, and changes in operating asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $50,071, an increase of interest receivable of $2,380, an increase in accounts payable and accrued expenses of $683,874 and a decrease in deferred revenue of $36,051.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by (used in) investing activities for the six months ended June 30, 2024 and 2023 were $1,051,868 and $(9,834,589), respectively, a positive change of $10,886,457, or 110.7%.

●

Net cash provided by investing activities for the six months ended June 30, 2024 was $1,051,868 which consisted of proceeds from the sale of short-term investments of $1,149,320, offset by aggregate payments for the purchase of short-term investments of $97,452.

●

Net cash used in investing activities for the six months ended June 30, 2023 was $9,834,589 which consisted of aggregate payments for the purchase of short-term investments of $10,352,410 offset by proceeds from the sale of short-term investments of $517,821.

Net Cash Provided by (Used in) Financing Activities

Net cash provided (used) in financing activities for the six months ended June 30, 2024 and 2023 was $1,500,106 and $(130,959), respectively, a positive change of $1,631,065 or 1,245.5%.

●

Net cash provided by financing activities for the six months ended June 30, 2024 was $1,500,106 which consisted of net proceeds from sale of common stock and pre-funded warrants of $1,673,216 and proceeds from the exercise of pre-funded warrants of $3, offset by the purchase of treasury stock of $173,113.

●

Net cash used in financing activities for the six months ended June 30, 2023 was $130,959 which was solely for the purchase of treasury stock.

-34-

Cash Requirements

We believe that our current cash and cash equivalent amount and short-term investment amount will provide sufficient cash required to meet our obligations for a minimum of twelve months from the date of this filing.

Other than cash requirements pursuant to research and development agreements, we currently have no other material commitments for any capital expenditures.

Liquidity

As reflected in the accompanying unaudited consolidated financial statements, we generated a net loss of $1,733,446 and used cash in operations of $1,322,582 during the six months ended June 30, 2024. Additionally, we have an accumulated deficit of $12,605,257 on June 30, 2024. As of June 30, 2024, we had working capital of $6,405,949.

The positive working capital serves to mitigate the conditions that historically raised substantial doubt about our ability to continue as a going concern. We believe that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.

Off-Balance Sheet Arrangements

None.

Critical Accounting Estimates

Stock-Based Compensation

Research and Development

In accordance with ASC 730-10, “Research and Development-Overall,” research and development costs are expensed when incurred.

Recently Issued Accounting Standards Not Yet Effective or Adopted

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying unaudited condensed consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this Item as we are a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including the principal executive officer and the principal financial officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act, as of the end of the period covered by this report. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures were not effective as of June 30, 2024.

-35-

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses which we identified in our internal control over financial reporting:

	●	We lack segregation of duties within accounting functions duties as a result of our limited financial resources to support hiring of personnel; and.

	●	We have not implemented adequate system and manual controls.

Until such time as we expand our staff to include additional accounting personnel, it is likely we will continue to report material weaknesses in our internal control over financial reporting.

A material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-36-

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

ITEM 1A. RISK FACTORS

Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024 (“Annual Report”). There have been no material changes in our risk factors from those previously disclosed in our Annual Report. You should carefully consider the risks described in our Annual Report, which could materially affect our business, financial condition or future results. The risks described in our Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

Issuer Purchases of Equity Securities

On January 26, 2023, our Board of Directors authorized a stock repurchase plan to repurchase up to $1,000,000 of our issued and outstanding common stock, from time to time, with such program to be in place until December 31, 2023. On January 9, 2024, our Board of Directors approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company’s common stock until March 31, 2024 and on April 4, 2024, the stock Repurchase Plan was extended to April 30, 2024. During the year ended December 31, 2023, we purchased 252,855 shares of common stock for a cost of $471,121, which is reflected in treasury stock on the accompanying unaudited consolidated balance sheet. During the six months ended June 30, 2024, we purchased 102,855 shares of common stock for a cost of $173,113. As of June 30, 2024, we have repurchased an aggregate of 355,710 shares of our common stock for a total cost of $644,234 pursuant to its Stock Repurchase Program.

The following is a summary of our common stock repurchases during the quarterly period ended June 30, 2024:

Period	Total number of shares purchased		Average price paid per share		Total number of shares purchased as part of publicly announced program		Maximum number (or approximate dollar value) of shares that may yet be purchased under the program
April 1, 2024 through April 30, 2024		30,065	$	1.92		30,065
May 1, 2024 through May 31, 2024		-	$	-		-
June 1, 2024 through June 30, 2024		-	$	-		-
Total		30,065	$	1.92		30,065	$	0

-37-

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

During the fiscal quarter ended June 30, 2024, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

ITEM 6. EXHIBITS

Exhibit No.		Description of Exhibits
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document.
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Filed herewith.

Furnished herewith.

-38-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SILO PHARMA, INC.

Dated: August 13, 2024	By:	/s/ Eric Weisblum
	Name:	Eric Weisblum
	Title:	Chairman and Chief Executive Officer (Principal Executive Officer)

Dated: August 13, 2024	By:	/s/ Daniel Ryweck
	Name:	Daniel Ryweck
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

-39-

0.31 0.32 0.59 0.61 2959800 3052666 3153852 3156311 false --12-31 Q2 0001514183 0001514183 2024-01-01 2024-06-30 0001514183 2024-08-13 0001514183 2024-06-30 0001514183 2023-12-31 0001514183 2024-04-01 2024-06-30 0001514183 2023-04-01 2023-06-30 0001514183 2023-01-01 2023-06-30 0001514183 us-gaap:CommonStockMember 2023-12-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001514183 us-gaap:TreasuryStockCommonMember 2023-12-31 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001514183 us-gaap:RetainedEarningsMember 2023-12-31 0001514183 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001514183 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001514183 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001514183 2024-01-01 2024-03-31 0001514183 us-gaap:CommonStockMember 2024-03-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001514183 us-gaap:TreasuryStockCommonMember 2024-03-31 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001514183 us-gaap:RetainedEarningsMember 2024-03-31 0001514183 2024-03-31 0001514183 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001514183 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001514183 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001514183 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001514183 us-gaap:CommonStockMember 2024-06-30 0001514183 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001514183 us-gaap:TreasuryStockCommonMember 2024-06-30 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001514183 us-gaap:RetainedEarningsMember 2024-06-30 0001514183 us-gaap:CommonStockMember 2022-12-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001514183 us-gaap:RetainedEarningsMember 2022-12-31 0001514183 2022-12-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001514183 2023-01-01 2023-03-31 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001514183 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001514183 us-gaap:CommonStockMember 2023-03-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001514183 us-gaap:RetainedEarningsMember 2023-03-31 0001514183 2023-03-31 0001514183 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001514183 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001514183 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001514183 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001514183 us-gaap:CommonStockMember 2023-06-30 0001514183 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001514183 us-gaap:TreasuryStockCommonMember 2023-06-30 0001514183 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001514183 us-gaap:RetainedEarningsMember 2023-06-30 0001514183 2023-06-30 0001514183 2021-09-30 2021-09-30 0001514183 2021-09-30 0001514183 2023-10-01 0001514183 us-gaap:BankTimeDepositsMember 2024-06-30 0001514183 us-gaap:BankTimeDepositsMember 2023-12-31 0001514183 2023-01-01 2023-12-31 0001514183 us-gaap:StockOptionMember 2024-01-01 2024-06-30 0001514183 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001514183 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001514183 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001514183 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001514183 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001514183 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001514183 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001514183 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001514183 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001514183 us-gaap:NotesReceivableMember 2023-12-31 0001514183 srt:MinimumMember 2023-12-04 0001514183 srt:MaximumMember 2023-12-04 0001514183 srt:MinimumMember silo:AmendmentMember 2023-12-04 0001514183 srt:MaximumMember silo:AmendmentMember 2023-12-04 0001514183 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001514183 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0001514183 2022-08-29 2022-08-29 0001514183 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001514183 us-gaap:CommonStockMember 2024-06-04 2024-06-04 0001514183 silo:PreFundedWarrantSharesMember 2024-06-04 2024-06-04 0001514183 2024-06-04 2024-06-04 0001514183 silo:OfferingPurchasePriceMember 2024-06-04 2024-06-04 0001514183 silo:CommonWarrantSharesMember 2024-06-04 2024-06-04 0001514183 silo:CashFeeMember 2024-04-23 2024-04-23 0001514183 silo:ManagementFeeMember 2024-04-23 2024-04-23 0001514183 us-gaap:CommonStockMember 2024-04-23 2024-04-23 0001514183 us-gaap:IPOMember 2024-06-04 0001514183 silo:PlacementAgentMember 2024-01-01 2024-04-23 0001514183 us-gaap:CommonStockMember 2024-01-01 2024-04-23 0001514183 2024-01-01 2024-04-23 0001514183 silo:PreFundedWarrantSharesMember 2024-01-01 2024-04-23 0001514183 us-gaap:IPOMember 2024-01-01 2024-04-23 0001514183 2024-04-23 0001514183 silo:PreFundedWarrantSharesMember 2024-01-01 2024-06-30 0001514183 us-gaap:WarrantMember 2024-06-30 0001514183 srt:DirectorMember silo:StockRepurchasePlanMember 2022-01-26 2022-01-26 0001514183 2024-01-09 2024-01-09 0001514183 silo:StockRepurchasePlanMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001514183 silo:StockRepurchasePlanMember us-gaap:CommonStockMember 2024-06-30 0001514183 silo:TwoThousandTwentyOmnibusEquityIncentivePlanMember 2021-01-18 0001514183 srt:MinimumMember srt:BoardOfDirectorsChairmanMember 2024-01-01 2024-06-30 0001514183 srt:MaximumMember srt:BoardOfDirectorsChairmanMember 2024-01-01 2024-06-30 0001514183 silo:StockWarrantsMember 2024-06-04 2024-06-04 0001514183 silo:StockWarrantsMember 2024-06-30 0001514183 silo:StockWarrantsMember us-gaap:CommonStockMember 2024-06-04 2024-06-04 0001514183 silo:PlacementAgentMember 2024-06-04 2024-06-04 0001514183 silo:StockOptionsMember 2023-12-30 0001514183 silo:StockOptionsMember 2023-12-31 2023-12-31 0001514183 silo:StockOptionsMember 2024-01-01 2024-06-30 0001514183 silo:StockOptionsMember 2024-06-30 0001514183 us-gaap:WarrantMember 2023-12-30 0001514183 us-gaap:WarrantMember 2023-12-31 2023-12-31 0001514183 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001514183 us-gaap:WarrantMember 2024-06-30 0001514183 silo:OneLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001514183 silo:OneLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001514183 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember silo:TwoLicensorMember 2024-01-01 2024-06-30 0001514183 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember silo:TwoLicensorMember 2023-01-01 2023-06-30 0001514183 silo:EricWeisblumMember 2022-10-12 2022-10-12 0001514183 silo:EricWeisblumMember 2022-10-12 0001514183 srt:BoardOfDirectorsChairmanMember silo:EricWeisblumMember 2022-10-12 0001514183 silo:MrWeisblumMember 2022-10-12 0001514183 silo:MrWeisblumMember 2023-09-01 2023-09-30 0001514183 silo:MrWeisblumMember 2022-10-01 2022-10-31 0001514183 silo:DanielRyweckMember 2022-10-12 2022-10-12 0001514183 silo:DrJamesKuoMember 2022-01-27 2022-01-27 0001514183 silo:DrJamesKuoMember 2022-01-27 0001514183 silo:DrJamesKuoMember 2022-10-31 0001514183 silo:DrJamesKuoMember 2023-10-31 0001514183 silo:DrJamesKuoMember 2024-01-01 2024-06-30 0001514183 us-gaap:MeasurementInputRiskFreeInterestRateMember silo:DrJamesKuoMember 2024-01-01 2024-06-30 0001514183 us-gaap:MeasurementInputExpectedDividendRateMember silo:DrJamesKuoMember 2024-01-01 2024-06-30 0001514183 us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-06-30 0001514183 us-gaap:MeasurementInputPriceVolatilityMember silo:DrJamesKuoMember 2024-01-01 2024-06-30 0001514183 silo:StockOptionsMember silo:DrJamesKuoMember 2024-06-30 0001514183 silo:ThirdAmendmentMember silo:UniversityOfMarylandBaltimoreMember 2022-01-01 2022-12-31 0001514183 silo:UniversityOfMarylandBaltimoreMember 2023-01-01 2023-06-30 0001514183 silo:ExtensionFeeMember silo:UniversityOfMarylandBaltimoreMember 2023-02-01 2023-02-28 0001514183 us-gaap:LicenseMember silo:UniversityOfMarylandBaltimoreMember 2023-02-01 2023-02-28 0001514183 silo:UniversityOfMarylandBaltimoreMember 2023-08-01 2023-08-31 0001514183 us-gaap:LicenseMember silo:UniversityOfMarylandBaltimoreMember 2023-08-01 2023-08-31 0001514183 silo:MasterLincenseAgreementMember 2024-01-01 2024-06-30 0001514183 us-gaap:LicenseMember silo:MasterLincenseAgreementMember 2024-01-01 2024-06-30 0001514183 silo:MasterLincenseAgreementMember 2022-02-01 2022-02-28 0001514183 us-gaap:LicenseMember 2024-01-01 2024-06-30 0001514183 silo:MasterLincenseAgreementMember 2024-06-30 0001514183 us-gaap:LicenseMember silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2024-01-01 2024-06-30 0001514183 silo:MasterLincenseAgreementMember 2023-12-31 0001514183 silo:SublicenseAgreementMember 2021-04-01 2021-04-30 0001514183 silo:MasterLincenseAgreementMember 2023-01-01 2023-06-30 0001514183 silo:MasterLincenseAgreementMember silo:SublicenseAgreementMember 2024-06-30 0001514183 silo:SublicenseAgreementMember 2023-12-31 0001514183 us-gaap:LicenseMember 2024-06-30 0001514183 silo:ThirdPaymentMember 2024-06-30 0001514183 silo:PatentProductsMember 2024-01-01 2024-06-30 0001514183 2024-06-28 0001514183 2024-06-28 2024-06-28 0001514183 silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2024-01-01 2024-06-30 0001514183 silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2021-01-01 2021-01-05 0001514183 silo:SeriesMConvertiblePreferredMember 2021-04-12 0001514183 silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2021-04-01 2021-04-12 0001514183 silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2021-04-12 0001514183 silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2024-06-30 0001514183 silo:LicenseFeeRevenuesMember silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2024-06-30 0001514183 silo:LicenseFeeRevenuesMember silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2023-06-30 0001514183 silo:CustomerPatentLicenseAgreementWithAikidoPharmaIncMember 2023-12-31 0001514183 silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember 2024-01-01 2024-06-30 0001514183 silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember 2021-04-01 2021-04-30 0001514183 silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember 2023-06-30 0001514183 silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember 2024-06-30 0001514183 silo:CustomerSublicenseAgreementWithAikidoPharmaIncMember 2023-12-31 0001514183 silo:SponsoredStudyAgreementMember 2021-01-05 0001514183 silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember silo:SponsoredStudyAgreementMember 2021-01-05 0001514183 silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember 2021-01-05 0001514183 silo:InvestigatorSponsoredStudyAgreementWithUniversityOfMarylandBaltimoreMember 2021-01-01 2021-12-31 0001514183 silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember 2021-06-01 2021-06-01 0001514183 silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember 2022-12-31 0001514183 silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember 2021-12-31 0001514183 silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2024-01-01 2024-06-30 0001514183 silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2023-01-01 2023-06-30 0001514183 silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember 2021-09-01 2021-09-01 0001514183 silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember 2022-08-31 2022-08-31 0001514183 silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember 2024-06-30 0001514183 silo:SponsoredResearchAgreementWithUniversityOfMarylandBaltimoreMember 2023-12-31 0001514183 silo:FirstPaymentMember silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2021-11-01 2021-11-30 0001514183 silo:SecondPaymentMember silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2022-07-01 2022-07-31 0001514183 silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2023-08-01 2023-08-31 0001514183 silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2023-01-01 2023-12-31 0001514183 silo:SponsoredResearchAgreementWithColumbiaUniversityMember 2024-06-30 0001514183 silo:ResearchAgreementWithReprocellMember 2022-10-25 2022-10-25 0001514183 silo:ResearchAgreementWithReprocellMember 2022-12-31 0001514183 silo:ResearchAgreementWithReprocellMember 2024-01-01 2024-06-30 0001514183 silo:ResearchAgreementWithReprocellMember 2023-01-01 2023-06-30 0001514183 silo:ResearchAgreementsWithUppertonPharmaSolutionsMember 2023-10-16 2023-10-16 0001514183 silo:UppertonResearchAgreementsMember 2023-01-01 2023-12-31 0001514183 silo:ResearchAgreementsWithUppertonPharmaSolutionsMember 2024-01-01 2024-06-30 0001514183 silo:ResearchAgreementsWithUppertonPharmaSolutionsMember 2023-01-01 2023-06-30 0001514183 silo:ResearchAgreementWithReprocellMember 2024-06-30 0001514183 silo:ResearchAgreementWithReprocellMember 2023-12-31 0001514183 silo:AmplifyBioResearchAgreementMember 2024-01-01 2024-06-30 0001514183 silo:SponsoredResearchAgreementWithTheRegentsOfTheUniversityOfCaliforniaMember 2023-12-31 0001514183 silo:AmplifyBioResearchAgreementsMember 2024-01-01 2024-06-30 0001514183 silo:AmplifyBioResearchAgreementsMember 2023-01-01 2023-06-30 0001514183 silo:AmplifyBioResearchAgreementMember 2023-01-01 2023-06-30 0001514183 silo:SeverPharmaMember 2024-01-01 2024-06-30 0001514183 silo:ResearchAgreementWithSeverPharmaSolutionsMember 2024-01-01 2024-06-30 0001514183 silo:ResearchAgreementWithAmplifyBioMember 2023-01-01 2023-06-30 0001514183 silo:JVAgreementMember 2024-01-01 2024-06-30 0001514183 silo:JointVentureAgreementWithZylTherapeuticsIncMember 2024-01-01 2024-06-30 0001514183 silo:AmendedServiceAgreementMember 2021-09-10 2021-09-10 0001514183 silo:AmendedServiceAgreementMember 2024-01-01 2024-06-30 0001514183 silo:AmendedServiceAgreementMember 2023-01-01 2023-06-30 0001514183 silo:PaymentOneMember 2024-01-01 2024-06-30 0001514183 silo:PaymentTwoMember 2024-01-01 2024-06-30 0001514183 silo:PaymentThreeMember 2024-01-01 2024-06-30 0001514183 silo:PaymentFourMember 2024-01-01 2024-06-30 0001514183 silo:PaymentFiveMember 2024-01-01 2024-06-30 0001514183 silo:PaymentOneMember 2024-01-01 2024-06-30 0001514183 silo:PaymentTwoMember 2024-01-01 2024-06-30 0001514183 silo:PaymentThreeMember 2024-01-01 2024-06-30 0001514183 us-gaap:SubsequentEventMember 2024-07-18 2024-07-18 0001514183 us-gaap:SubsequentEventMember 2024-07-31 2024-07-31 0001514183 silo:PlacementAgentMember 2024-01-01 2024-06-30 0001514183 silo:PlacementAgentMember 2024-06-30 0001514183 silo:CommonWarrantSharesMember silo:PlacementAgentMember 2024-01-01 2024-06-30 0001514183 2024-04-23 2024-04-23 0001514183 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-07-18 2024-07-18 0001514183 us-gaap:SubsequentEventMember 2024-07-18 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:GBP

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF SILO PHARMA, INC.

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Eric Weisblum, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Silo Pharma, Inc. (the “registrant”) for the period ended June 30, 2024;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	SILO PHARMA, INC.

Dated: August 13, 2024	By:	/s/ Eric Weisblum
	Name:	Eric Weisblum
	Title:	Chairman and Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER OF SILO PHARMA, INC.

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Daniel Ryweck, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Silo Pharma, Inc. (the “registrant”) for the period ended June 30, 2024;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	SILO PHARMA, INC.

Dated: August 13, 2024	By:	/s/ Daniel Ryweck
	Name:	Daniel Ryweck
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of Silo Pharma, Inc. (the “Company”) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Eric Weisblum, Chief Executive Officer of the Company, certify, pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	SILO PHARMA, INC.

Dated: August 13, 2024	By:	/s/ Eric Weisblum
	Name:	Eric Weisblum
	Title:	Chairman and Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of Silo Pharma, Inc. (the “Company”) for the period ended June 30, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Daniel Ryweck, Chief Financial Officer of the Company, certify, pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	SILO PHARMA, INC.

Dated: August 13, 2024	By:	/s/ Daniel Ryweck
	Name:	Daniel Ryweck
	Title:	Chief Financial Officer (Principal Financial Officer)

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Aug. 13, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Information [Line Items]
Entity Registrant Name	SILO PHARMA, INC.
Entity Central Index Key	0001514183
Entity File Number	001-41512
Entity Tax Identification Number	27-3046338
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	677 N. Washington Boulevard
Entity Address, City or Town	Sarasota
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34236
Entity Phone Fax Numbers [Line Items]
City Area Code	(718)
Local Phone Number	400-9031
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	SILO
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		4,484,456

Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 4,506,300	$ 3,524,308
Short-term investments	3,102,240	4,140,880
Prepaid expenses and other current assets	120,288	15,970
Total Current Assets	7,728,828	7,681,158
LONG-TERM ASSETS:
Prepaid expenses and other assets - non-current	62,064	64,983
Intangible assets, net	247,400
Total Long-Term Assets	309,464	64,983
Total Assets	8,038,292	7,746,141
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,250,777	703,488
Deferred revenue - current portion	72,102	72,102
Total Current Liabilities	1,322,879	775,590
LONG TERM LIABILITIES:
Deferred revenue - long-term portion	757,629	793,680
Total Long Term Liabilities	757,629	793,680
Total Liabilities	2,080,508	1,569,270
Commitment and Contingencies (see Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of June 30, 2024 and December 31, 2023
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,076,528 and 3,159,096 shares issued and 3,720,818 and 2,906,241 shares outstanding at June 30, 2024 and December 31, 2023, respectively	408	316
Additional paid-in capital	19,198,841	17,525,714
Treasury stock, at cost (355,710 and 252,855 shares on June 30, 2024 and December 31, 2023, respectively)	(644,234)	(471,121)
Accumulated other comprehensive income (loss)	8,026	(6,227)
Accumulated deficit	(12,605,257)	(10,871,811)
Total Stockholders’ Equity	5,957,784	6,176,871
Total Liabilities and Stockholders’ Equity	$ 8,038,292	$ 7,746,141

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares designated
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	4,076,528	3,159,096
Common stock, shares outstanding	3,720,818	2,906,241
Treasury stock, shares	355,710	252,855

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
LICENSE FEE REVENUE	$ 18,025	$ 18,025	$ 36,051	$ 36,051
COST OF REVENUES	1,459	1,459	2,919	2,919
GROSS PROFIT	16,566	16,566	33,132	33,132
OPERATING EXPENSES:
Compensation expense	168,381	169,186	341,727	331,443
Professional fees	386,465	570,295	641,067	935,565
Research and development	392,824	130,719	774,889	333,632
Insurance expense	21,101	22,251	42,805	46,896
Selling, general and administrative expenses	50,569	239,100	114,931	304,066
Total operating expenses	1,019,340	1,131,551	1,915,419	1,951,602
LOSS FROM OPERATIONS	(1,002,774)	(1,114,985)	(1,882,287)	(1,918,470)
OTHER INCOME (EXPENSE):
Interest and dividend income, net	77,042	109,584	165,219	173,972
Interest expense	(1,859)	(1,863)	(3,729)	(3,518)
Net realized loss on short-term investments	(1,259)	(2,179)	(1,025)	(2,179)
Penalty from early termination of certificate of deposit				(166,034)
Net unrealized loss on equity investments		(3,508)		(3,118)
Foreign currency transaction loss	(2,929)		(11,624)
Total other income (expense)	70,995	102,034	148,841	(877)
LOSS BEFORE PROVISION FOR INCOME TAXES	(931,779)	(1,012,951)	(1,733,446)	(1,919,347)
Provision for income taxes
NET LOSS	(931,779)	(1,012,951)	(1,733,446)	(1,919,347)
COMPREHENSIVE LOSS:
Net loss	(931,779)	(1,012,951)	(1,733,446)	(1,919,347)
Other comprehensive income (loss):
Unrealized (loss) income on short-term investments	(18,078)	(8,520)	14,253	(3,281)
Total comprehensive loss	$ (949,857)	$ (1,021,471)	$ (1,719,193)	$ (1,922,628)
NET LOSS PER COMMON SHARE:
Basic (in Dollars per share)	$ (0.31)	$ (0.32)	$ (0.59)	$ (0.61)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in Shares)	3,052,666	3,153,852	2,959,800	3,156,311

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net Loss Per Common Share Diluted	$ (0.31)	$ (0.32)	$ (0.59)	$ (0.61)
Weighted Average Common Shares Outstanding Diluted	3,052,666	3,153,852	2,959,800	3,156,311

Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid In Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 316	$ 17,511,589			$ (7,171,128)	$ 10,340,777
Balance (in Shares) at Dec. 31, 2022	3,158,797
Accretion of stock options expense to stock based compensation		4,237				4,237
Accumulated other comprehensive income (loss)- short-term investments				$ 5,239		5,239
Net loss					(906,396)	(906,396)
Balance at Mar. 31, 2023	$ 316	17,515,826		5,239	(8,077,524)	9,443,857
Balance (in Shares) at Mar. 31, 2023	3,158,797
Balance at Dec. 31, 2022	$ 316	17,511,589			(7,171,128)	10,340,777
Balance (in Shares) at Dec. 31, 2022	3,158,797
Net loss						(1,919,347)
Balance at Jun. 30, 2023	$ 311	17,405,310	$ (16,201)	(3,281)	(9,090,475)	8,295,664
Balance (in Shares) at Jun. 30, 2023	3,108,797		7,335
Balance at Mar. 31, 2023	$ 316	17,515,826		5,239	(8,077,524)	9,443,857
Balance (in Shares) at Mar. 31, 2023	3,158,797
Purchase of treasury stock			$ (130,959)			(130,959)
Purchase of treasury stock (in Shares)			57,335
Accretion of stock options expense to stock based compensation		4,237				4,237
Cancellation of treasury stock	$ (5)	(114,753)	$ 114,758
Cancellation of treasury stock (in Shares)	(50,000)		(50,000)
Accumulated other comprehensive income (loss)- short-term investments				(8,520)		(8,520)
Net loss					(1,012,951)	(1,012,951)
Balance at Jun. 30, 2023	$ 311	17,405,310	$ (16,201)	(3,281)	(9,090,475)	8,295,664
Balance (in Shares) at Jun. 30, 2023	3,108,797		7,335
Balance at Dec. 31, 2023	$ 316	17,525,714	$ (471,121)	(6,227)	(10,871,811)	6,176,871
Balance (in Shares) at Dec. 31, 2023	3,159,096		252,855
Purchase of treasury stock			$ (115,452)			(115,452)
Purchase of treasury stock (in Shares)			72,790
Accumulated other comprehensive income (loss)- short-term investments				32,331		32,331
Net loss					(801,667)	(801,667)
Balance at Mar. 31, 2024	$ 316	17,525,714	$ (586,573)	26,104	(11,673,478)	5,292,083
Balance (in Shares) at Mar. 31, 2024	3,159,096		325,645
Balance at Dec. 31, 2023	$ 316	17,525,714	$ (471,121)	(6,227)	(10,871,811)	6,176,871
Balance (in Shares) at Dec. 31, 2023	3,159,096		252,855
Net loss						(1,733,446)
Balance at Jun. 30, 2024	$ 408	19,198,841	$ (644,234)	8,026	(12,605,257)	5,957,784
Balance (in Shares) at Jun. 30, 2024	4,076,528		355,710
Balance at Mar. 31, 2024	$ 316	17,525,714	$ (586,573)	26,104	(11,673,478)	5,292,083
Balance (in Shares) at Mar. 31, 2024	3,159,096		325,645
Sale of common stock and pre-funded warrants	$ 89	1,673,127				1,673,216
Sale of common stock and pre-funded warrants (in Shares)	883,395
Exercise of pre-funded warrants	$ 3					3
Exercise of pre-funded warrants (in Shares)	34,037
Purchase of treasury stock			$ (57,661)			(57,661)
Purchase of treasury stock (in Shares)			30,065
Accumulated other comprehensive income (loss)- short-term investments				(18,078)		(18,078)
Net loss					(931,779)	(931,779)
Balance at Jun. 30, 2024	$ 408	$ 19,198,841	$ (644,234)	$ 8,026	$ (12,605,257)	$ 5,957,784
Balance (in Shares) at Jun. 30, 2024	4,076,528		355,710

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,733,446)	$ (1,919,347)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation and professional fees		8,474
Amortization of prepaid stock-based professional fees		67,550
Net realized loss on short-term investments	1,025	2,179
Net unrealized loss on equity investments		3,118
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(101,399)	(50,071)
Interest receivable		(2,380)
Accounts payable and accrued expenses	299,889	683,874
Deferred revenue	(36,051)	(36,051)
NET CASH USED IN OPERATING ACTIVITIES	(1,569,982)	(1,242,654)
CASH FLOWS FROM INVESTING ACTIVITIES:
Sale of short-term investments	1,149,320	517,821
Purchase of short-term investments	(97,452)	(10,352,410)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	1,051,868	(9,834,589)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock and pre-funded warrants	1,673,216
Proceeds from exercise of pre-funded warrants	3
Purchase of treasury stock	(173,113)	(130,959)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	1,500,106	(130,959)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	981,992	(11,208,202)
CASH AND CASH EQUIVALENTS - beginning of the period	3,524,308	11,367,034
CASH AND CASH EQUIVALENTS - end of the period	4,506,300	158,832
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	3,729	3,518
Income taxes
Non-cash investing and financing activities:
Change in accumulated other comprehensive income	14,253	3,281
Cancellation of treasury stock		114,758
Intangible assets acquired with accounts payable	$ 247,400

Organization and Business

6 Months Ended

Jun. 30, 2024

Organization and Business [Abstract]

ORGANIZATION AND BUSINESS

NOTE 1 – ORGANIZATION AND BUSINESS

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

Liquidity

Use of Estimates

Cash and Cash Equivalents

Short-Term Investments

Equity Investments, at Fair Value

Note Receivable

Prepaid Expenses

Intangible Assets

Revenue Recognition

The Company records interest and dividend income on an accrual basis to the extent that the Company expects to collect such amounts.

Cost of Revenues

Stock-Based Compensation

Income Taxes

Research and Development

Leases

Net Loss per Common Share

The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the six months ended June 30, 2024 and 2023:

	June 30,		June 30,
	2024		2023
Stock options		26,850		28,850
Warrants		1,390,819		404,580
		1,417,669		433,430

Recent Accounting Pronouncements

Fair Value of Financial Instruments and Fair Value Measurements

6 Months Ended

Jun. 30, 2024

Fair Value of Financial Instruments and Fair Value Measurements [Abstract]

FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

NOTE 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Fair Value Measurements and Fair Value of Financial Instruments

	Level 1 -	Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

	Level 2 -	Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

	Level 3 -	Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023.

	June 30, 2024						December 31, 2023
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Short-term investments	$	3,102,240	$	-	$	-	$	4,140,880	$	-	$	-

The Company’s short-term investments and equity investments are level 1 measurements and are based on redemption value at each date.

Short-Term Investments – Debt Securities, at Fair Value

The following table summarizes activity in the Company’s short-term investments, at fair value for the periods presented:

	Six Months Ended June 30,			Six Months Ended June 30,
	2024			2023
Balance, beginning of period	$	4,140,880		$	-
Additions		97,452			10,352,410
Sales at original cost		(1,149,320	)		(517,821	)
Net realized loss on short-term investments		(1,025	)		(2,179	)
Unrealized gain (loss)		14,253			(3,281	)
Balance, end of period	$	3,102,240		$	9,829,129

Note Receivable

6 Months Ended

Jun. 30, 2024

Note Receivable [Abstract]

NOTE RECEIVABLE

NOTE 4 – NOTE RECEIVABLE

On June 30, 2024 and December 31, 2023, note receivable consisted of the following:

	June 30,			December 31,
	2024			2023
Principal amount of note receivable	$	60,000		$	60,000
Accrued interest receivable		9,600			9,600
Subtotal		69,600			69,600
Less: allowance for doubtful accounts		(69,600	)		(69,600	)
Note receivable – current		-			-

Intangible Assets

6 Months Ended

Jun. 30, 2024

Intangible Assets [Abstract]

INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

On June 30, 2024 and December 31, 2023, intangible assets consisted of the following:

	Useful life	June 30, 2024		December 31, 2023
License	20 years	$	247,400	$	-
Less: accumulated amortization			-		-
		$	247,400	$	-

Amortization of intangible assets with finite lives attributable to future periods is as follows:

Year ending June 30:	Amount
2025	$	12,370
2026		12,370
2027		12,370
2028		12,370
2029		12,370
Thereafter		185,550
Total	$	247,400

Stockholders’ Equity

6 Months Ended

Jun. 30, 2024

Stockholders’ Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 6 – STOCKHOLDERS’ EQUITY

Shares Authorized

Common Stock Issued for Services

Sale of Common Stock and Warrants

Stock Repurchase Plan

Stock Options

Stock option activities for the six months ended June 30, 2024 are summarized as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance Outstanding, December 31, 2023		28,850		$	7.28		5.31	$	8,610
Expired		(2,000	)		0.005		-		-
Balance Outstanding, June 30, 2024		26,850		$	7.82		5.19	$	3,980
Exercisable, June 30, 2024		26,850		$	7.82		5.19	$	3,980

Stock Warrants

Warrant activities for the six months ended June 30, 2024 are summarized as follows:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance Outstanding, December 31, 2023		404,580		$	14.05		2.31	$	-
Granted		1,020,276			2.04		-		-
Exercised		(34,037	)		0.0001
Balance Outstanding, June 30, 2024		1,390,819		$	5.58		4.03	$	-
Exercisable, June 30, 2024		1,390,819		$	5.58		4.03	$	-

Concentrations

6 Months Ended

Jun. 30, 2024

Concentrations [Abstract]

CONCENTRATIONS

NOTE 7 – CONCENTRATIONS

Customer concentration

For the six months ended June 30, 2024 and 2023, one licensee accounted for 100% total revenues from customer license fees.

Vendor concentrations

Commitments and Contingencies

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 8 – COMMITMENTS AND CONTINGENCIES

Employment Agreements

Eric Weisblum

Daniel Ryweck

Dr. James Kuo

License Agreements between the Company and Vendors

University of Maryland, Baltimore - License Agreement for Development and Use of Central Nervous System-Homing Peptides

Commercial Evaluation License and Option Agreement with the University of Maryland, Baltimore

University of Maryland, Baltimore - License Agreement for Development and Use of Joint-Homing Peptides

Commercial Evaluation License and Option Agreement with the University of Maryland, Baltimore

Master License Agreement with the University of Maryland, Baltimore

Milestone	Payment
Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product	$	50,000
Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product	$	100,000
Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product	$	250,000
Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product	$	500,000
Achievement of First Commercial Sale of Licensed Product	$	1,000,000

Royalty Payments Terms:

(i)

3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and

(ii)

5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and

(iii)

minimum annual royalty payments, as follows:

Years	Minimum Annual Royalty
Prior to First Commercial Sale	$	N/A
Year of First Commercial Sale	$	N/A
First calendar year following the First Commercial Sale	$	25,000
Second calendar year following the First Commercial Sale	$	25,000
Third calendar year following the First Commercial Sale	$	100,000

Exclusive License Agreement with the Trustees of Columbia University in the City of New York

(i)

an initial license fee of $50,000 due on the Effective Date and included in intangible assets and accounts payable on the accompanying unaudited consolidated balance sheet as of June 30, 2024.

(ii)

(iii)

Royalties as follows:

(A)

(1)

4% of Net Sales of Patent Products; and

(2)

2% of Net Sales of Technology Products.

(B)

(iv)

(v)

The Company shall reimburse Columbia for patent expenses as follows:

(i)

(ii)

Unreimbursed Patent Expenses that Columbia incurred for legal activities occurring before September 30, 2021 are “Past Patent Expenses.”

(iii)

(iv)

The Company will pay any additional unreimbursed Past Patent Expenses within thirty (30) days after receiving an invoice from Columbia for the additional Past Patent Expenses.

(v)

(vi)

License Agreements between the Company and Customer

Customer Patent License Agreement with Aikido Pharma Inc.

Customer Sublicense Agreement with Aikido Pharma Inc.

Sponsored Study and Research Agreements between the Company and Vendors

Investigator-Sponsored Study Agreement with University of Maryland, Baltimore

Sponsored Research Agreement with The Regents of the University of California

Sponsored Research Agreement with University of Maryland, Baltimore

	Payment
1	$	92,095	Paid upon execution of the July 2021 Sponsored Research Agreement
2	$	92,095	Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement
3	$	92,095	Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement

Sponsored Research Agreement with Columbia University

Research Agreement with Reprocell

Research Agreements with Upperton Pharma Solutions

Research Agreement with AmplifyBio

Research Agreement with Sever Pharma Solutions

On June 30, 2024, future amounts due under sponsored study and research agreements between the Company and vendors is as follows:

Year ended June 30,	Amount
2025	$	1,878,928
Total	$	1,878,928

Joint Venture Agreement with Zylö Therapeutics, Inc.

Amended Service Agreement

Subsequent Events

6 Months Ended

Jun. 30, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

Exclusive License Agreement with the Trustees of Columbia University in the City of New York

Sale of Common Stock and Warrants

On April 23, 2024, the Company entered into an engagement agreement with H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as placement agent on a reasonable “best efforts” basis in connection with the Offering. The Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.5% of the gross proceeds from the sale of securities in the Offering and a management fee equal to 1.0% of the gross proceeds raised in the Offering. The Company also agreed to issue the Placement Agent (or its designees) a warrant (the “Placement Agent Warrant”) to purchase up to 7.5% of the aggregate number of shares of Common Stock sold in the offering. In connection with the July 18, 2024 Purchase Agreement, the Company paid the Placement Agent a cash fee and management fee of $178,500 and the Placement Agent received Placement Agent Warrants to purchase up to 57,273 shares of Common Stock, at an exercise price equal to 125.0% of the offering price per share of Common Stock, or $3.4375 per share. The Placement Agent Warrants are exercisable immediately upon issuance for a period of five years following the commencement of the sales pursuant to the Offering. In addition, the Company paid to pay the Placement Agent $25,000 for non-accountable expenses, $50,000 for legal expenses and other out-of-pocket expenses and $15,950 for clearing fees.

The Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale of the Common Warrant Shares (the “Resale Registration Statement”) within 45 calendar days of the date of the Purchase Agreement (the “Filing Date”), and to use commercially reasonable efforts to cause the Resale Registration Statement to be declared effective by the SEC within 75 calendar days following the date of the Filing Date and to keep the Resale Registration Statement effective at all times until the Holders no longer own any Common Warrants or Common Warrant Shares.

Pay vs Performance Disclosure - USD ($)	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (931,779)	$ (801,667)	$ (1,012,951)	$ (906,396)	$ (1,733,446)	$ (1,919,347)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy (Policies)

6 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

Liquidity

Liquidity

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Short-Term Investments

Short-Term Investments

Equity Investments, at Fair Value

Equity Investments, at Fair Value

Note Receivable

Note Receivable

Prepaid Expenses

Prepaid Expenses

Intangible Assets

Intangible Assets

Revenue Recognition

Revenue Recognition

The Company records interest and dividend income on an accrual basis to the extent that the Company expects to collect such amounts.

Cost of Revenues

Cost of Revenues

Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

Income Taxes

Income Taxes

Research and Development

Research and Development

Leases

Leases

Net Loss per Common Share

Net Loss per Common Share

The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the six months ended June 30, 2024 and 2023:

	June 30,		June 30,
	2024		2023
Stock options		26,850		28,850
Warrants		1,390,819		404,580
		1,417,669		433,430

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies [Abstract]

Schedule of Potentially Dilutive Shares

The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the six months ended June 30, 2024 and 2023:

	June 30,		June 30,
	2024		2023
Stock options		26,850		28,850
Warrants		1,390,819		404,580
		1,417,669		433,430

Fair Value of Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2024

Fair Value of Financial Instruments and Fair Value Measurements [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023.

	June 30, 2024						December 31, 2023
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Short-term investments	$	3,102,240	$	-	$	-	$	4,140,880	$	-	$	-

Schedule of Summarizes Activity in the Company’s Short Term Investments at Fair Value

The following table summarizes activity in the Company’s short-term investments, at fair value for the periods presented:

	Six Months Ended June 30,			Six Months Ended June 30,
	2024			2023
Balance, beginning of period	$	4,140,880		$	-
Additions		97,452			10,352,410
Sales at original cost		(1,149,320	)		(517,821	)
Net realized loss on short-term investments		(1,025	)		(2,179	)
Unrealized gain (loss)		14,253			(3,281	)
Balance, end of period	$	3,102,240		$	9,829,129

Note Receivable (Tables)

6 Months Ended

Jun. 30, 2024

Note Receivable [Abstract]

Schedule of Note Receivable

On June 30, 2024 and December 31, 2023, note receivable consisted of the following:

	June 30,			December 31,
	2024			2023
Principal amount of note receivable	$	60,000		$	60,000
Accrued interest receivable		9,600			9,600
Subtotal		69,600			69,600
Less: allowance for doubtful accounts		(69,600	)		(69,600	)
Note receivable – current		-			-

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2024

Intangible Assets [Abstract]

Schedule of Intangible Asset

On June 30, 2024 and December 31, 2023, intangible assets consisted of the following:

	Useful life	June 30, 2024		December 31, 2023
License	20 years	$	247,400	$	-
Less: accumulated amortization			-		-
		$	247,400	$	-

Schedule of Intangible Assets Finite Lives Attributable to Future Periods

Amortization of intangible assets with finite lives attributable to future periods is as follows:

Year ending June 30:	Amount
2025	$	12,370
2026		12,370
2027		12,370
2028		12,370
2029		12,370
Thereafter		185,550
Total	$	247,400

Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2024

Stockholders’ Equity [Abstract]

Schedule of Stock Option Activities

Stock option activities for the six months ended June 30, 2024 are summarized as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance Outstanding, December 31, 2023		28,850		$	7.28		5.31	$	8,610
Expired		(2,000	)		0.005		-		-
Balance Outstanding, June 30, 2024		26,850		$	7.82		5.19	$	3,980
Exercisable, June 30, 2024		26,850		$	7.82		5.19	$	3,980

Schedule of Warrant Activities

Warrant activities for the six months ended June 30, 2024 are summarized as follows:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance Outstanding, December 31, 2023		404,580		$	14.05		2.31	$	-
Granted		1,020,276			2.04		-		-
Exercised		(34,037	)		0.0001
Balance Outstanding, June 30, 2024		1,390,819		$	5.58		4.03	$	-
Exercisable, June 30, 2024		1,390,819		$	5.58		4.03	$	-

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies [Abstract]

Schedule of Milestone Payments

Milestone	Payment
Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product	$	50,000
Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product	$	100,000
Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product	$	250,000
Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product	$	500,000
Achievement of First Commercial Sale of Licensed Product	$	1,000,000

Schedule of Minimum Annual Royalty Payments

minimum annual royalty payments, as follows:

Years	Minimum Annual Royalty
Prior to First Commercial Sale	$	N/A
Year of First Commercial Sale	$	N/A
First calendar year following the First Commercial Sale	$	25,000
Second calendar year following the First Commercial Sale	$	25,000
Third calendar year following the First Commercial Sale	$	100,000

Schedule of Shall Pay UMB Fees

The Company may exercise the Option by giving UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement, the Company shall pay UMB the fees below:

	Payment
1	$	92,095	Paid upon execution of the July 2021 Sponsored Research Agreement
2	$	92,095	Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement
3	$	92,095	Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement

Schedule of Future Amounts Due Under Sponsored Study and Research Agreements

On June 30, 2024, future amounts due under sponsored study and research agreements between the Company and vendors is as follows:

Year ended June 30,	Amount
2025	$	1,878,928
Total	$	1,878,928

Organization and Business (Details) - USD ($)	Sep. 30, 2021	Oct. 01, 2023
Organization and Business [Abstract]
Purchase price	$ 60,000
Promissory note amounting	$ 60,000
Promissory note bears interest rate	8.00%	9.00%
Maturity date	Oct. 01, 2023	Dec. 30, 2023

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]
Net loss	$ (931,779)	$ (801,667)	$ (1,012,951)	$ (906,396)	$ (1,733,446)	$ (1,919,347)
Cash in operations					(1,322,582)
Accumulated deficit	(12,605,257)				(12,605,257)		$ (10,871,811)
Working capital	6,405,949				6,405,949
Federal deposit insurance corporation	250,000				250,000
Securities investor protection corporation	250,000				250,000
Penalty paid						166,034
Unrealized loss on short-term investments	(18,078)		(8,520)		14,253	(3,281)
Bad debt expense							69,600
Note receivable principal balance amount							60,000
Accrued interest receivable	9,600				9,600		9,600
Prepaid expenses and other current assets	120,288				120,288		15,970
Prepaid expenses and other assets – non-current	$ 62,064				$ 62,064		64,983
Useful life	20 years				20 years
Research and development cost	$ 392,824		$ 130,719		$ 774,889	$ 333,632
FDIC [Member]
Summary of Significant Accounting Policies [Line Items]
Federal deposit insurance corporation	$ 3,756,000				$ 3,756,000		$ 2,805,000

Summary of Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Shares - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Potentially Dilutive Shares [Line Items]
Potentially dilutive shares	1,417,669	433,430
Stock Options [Member]
Schedule of Potentially Dilutive Shares [Line Items]
Potentially dilutive shares	26,850	28,850
Warrants [Member]
Schedule of Potentially Dilutive Shares [Line Items]
Potentially dilutive shares	1,390,819	404,580

Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Level 1 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments	$ 3,102,240	$ 4,140,880
Level 2 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments
Level 3 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments

Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of Summarizes Activity in the Company’s Short Term Investments at Fair Value - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Short-Term Investments [Abstract]
Balance, beginning of period			$ 4,140,880
Additions			97,452	10,352,410
Sales at original cost			(1,149,320)	(517,821)
Net realized loss on short-term investments	$ (1,259)	$ (2,179)	(1,025)	(2,179)
Unrealized gain (loss)			14,253	(3,281)
Balance, end of period	$ 3,102,240	$ 9,829,129	$ 3,102,240	$ 9,829,129

Note Receivable (Details) - Notes Receivable [Member]	Dec. 31, 2023 USD ($)
Note Receivable [Line Items]
Estimated probable losses	$ 69,600
Note receivable principal balance	60,000
Accrued interest receivable	$ 9,600

Note Receivable (Details) - Schedule of Note Receivable - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Note Receivable [Abstract]
Principal amount of note receivable	$ 60,000	$ 60,000
Accrued interest receivable	9,600	9,600
Subtotal	69,600	69,600
Less: allowance for doubtful accounts	(69,600)	(69,600)
Note receivable – current

Intangible Assets (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Intangible assets	$ 247,400

Intangible Assets (Details) - Schedule of Intangible Asset - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Intangible Asset [Abstract]
License, Useful life	20 years
License	$ 247,400
Less: accumulated amortization
Total	$ 247,400

Intangible Assets (Details) - Schedule of Intangible Assets Finite Lives Attributable to Future Periods	Jun. 30, 2024 USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2025	$ 12,370
2026	12,370
2027	12,370
2028	12,370
2029	12,370
Thereafter	185,550
Total	$ 247,400

Stockholders’ Equity (Details) - USD ($)						3 Months Ended			4 Months Ended	6 Months Ended		12 Months Ended
Stockholders’ Equity (Details) - USD ($)	Jun. 04, 2024	Apr. 23, 2024	Jan. 09, 2024	Aug. 29, 2022	Jan. 26, 2022	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Apr. 23, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 04, 2023	Jan. 18, 2021
Stockholders’ Equity [Line Items]
Common stock, shares authorized						100,000,000				100,000,000		100,000,000
Shares authorized										105,000,000
Restricted common shares				20,000
Restricted common value (in Dollars)				$ 135,100
Restricted common share price (in Dollars per share)				$ 6.755
Stock-based professional fees (in Dollars)						$ 386,465		$ 570,295		$ 641,067	$ 935,565
Purchase price per share (in Dollars per share)	$ 2.1799
Purchased shares	34,037
Exercise price per share (in Dollars per share)	$ 0.0001
Aggregate shares of common warrants shares	917,432
Percentage of proceeds in offering		1.00%
Percentage of aggregate shares		7.50%
Cash fee and management fee (in Dollars)	$ 170,000
Percentage of exercise price of offering price per share	125.00%
Legal fees and expenses (in Dollars)										$ 65,833
Number of offering price per share (in Dollars per share)	$ 2.725
Aggregate gross proceeds (in Dollars)									$ 1,925,801
Amount of net proceeds (in Dollars)									1,673,216
Offering costs (in Dollars)		$ 260,950							$ 260,950
Underwriters warrants						34,037				34,037
Cash (in Dollars)						$ 3				$ 3
Repurchase of shares (in Dollars)						57,661	$ 115,452	130,959
Stock repurchase (in Dollars)			$ 1,000,000
Common stock purchase												252,855
Deferred compensation (in Dollars)						$ 0		$ 8,474		$ 0	8,474
Pre-Funded Warrant Shares [Member]
Stockholders’ Equity [Line Items]
Purchased shares	34,037
Exercise price per share (in Dollars per share)	$ 0.0001									$ 0.0001
Number of offering price per share (in Dollars per share)									$ 2.1799
Aggregate gross proceeds (in Dollars)									$ 74,201
Offering Purchase Price [Member]
Stockholders’ Equity [Line Items]
Purchase price per share (in Dollars per share)	$ 2.1799
Common Warrant Shares [Member]
Stockholders’ Equity [Line Items]
Purchased shares	1
Exercise price per share (in Dollars per share)	$ 2.06
Aggregate shares of common warrants shares	917,432
Warrant [Member]
Stockholders’ Equity [Line Items]
Underwriters warrants						34,037				34,037
Stock Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price per share (in Dollars per share)	$ 0.0001
Underwriters warrants						34,037				34,037
Cash (in Dollars)						$ 3				$ 3
Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares authorized													500,000,000
Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares authorized													100,000,000
Common Stock [Member]
Stockholders’ Equity [Line Items]
Shares authorized										100,000,000
Stock-based professional fees (in Dollars)										$ 0	$ 67,550
Agreed to sell investors shares	883,395
Purchase price per share (in Dollars per share)	$ 2.18
Purchased shares	68,807
Percentage of aggregate shares		7.50%
Percentage of exercise price of offering price per share	125.00%
Number of offering price per share (in Dollars per share)									$ 2.18
Underwriters warrants						34,037				34,037
Repurchase of shares (in Dollars)
Common stock purchase										102,855
Common stock purchase cost (in Dollars)						173,113				$ 173,113		$ 471,121
Common Stock [Member] \| Stock Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price per share (in Dollars per share)	$ 2.06
Common Stock [Member] \| Stock Repurchase Plan [Member]
Stockholders’ Equity [Line Items]
Common stock purchase										355,710
Common stock purchase cost (in Dollars)						644,234				$ 644,234
Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Shares authorized										5,000,000
Cash Fee [Member]
Stockholders’ Equity [Line Items]
Percentage of proceeds from the sale of securities		7.50%
Management Fee [Member]
Stockholders’ Equity [Line Items]
Percentage of proceeds in offering		1.00%
Placement Agent [Member]
Stockholders’ Equity [Line Items]
Purchased shares	68,807
Non-accountable expenses (in Dollars)									$ 25,000
Legal fees and expenses (in Dollars)									50,000
Clearing fees (in Dollars)									15,950
Amount of net proceeds (in Dollars)										$ 1,780,555
Offering costs (in Dollars)						$ 269,450				269,450
Placement Agent [Member] \| Common Warrant Shares [Member]
Stockholders’ Equity [Line Items]
Legal fees and expenses (in Dollars)										$ 50,000
Amendment [Member] \| Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares authorized													500,000,000
Amendment [Member] \| Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock, shares authorized													100,000,000
2020 Omnibus Equity Incentive Plan [Member]
Stockholders’ Equity [Line Items]
Common stock reserved and avail for issuance														170,000
Board of Directors [Member] \| Stock Repurchase Plan [Member]
Stockholders’ Equity [Line Items]
Repurchase of shares (in Dollars)					$ 1,000,000
Board of Directors Chairman [Member] \| Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock issued under the plan										300,000
Board of Directors Chairman [Member] \| Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock issued under the plan										470,000
IPO [Member]
Stockholders’ Equity [Line Items]
Offering price per share (in Dollars per share)	$ 2.725
Aggregate gross proceeds (in Dollars)									$ 2,000,002

Stockholders’ Equity (Details) - Schedule of Stock Option Activities - Stock Options [Member] - USD ($)		6 Months Ended
	Dec. 31, 2023	Jun. 30, 2024
Schedule of Stock Option Activities [Line Items]
Number of Options, Balance (in Shares)	28,850
Weighted Average Exercise Price, Balance	$ 7.28
Weighted Average Remaining Contractual Term (Years), Balance	5 years 3 months 21 days	5 years 2 months 8 days
Aggregate Intrinsic Value, Balance (in Dollars)	$ 8,610
Number of Options, Granted (in Shares)		(2,000)
Weighted Average Exercise Price, Granted		$ 0.005
Weighted Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted
Number of Options, Balance (in Shares)		26,850
Weighted Average Exercise Price, Balance		$ 7.82
Aggregate Intrinsic Value, Balance (in Dollars)		$ 3,980
Number of Options, Exercisable (in Shares)		26,850
Weighted Average Exercise Price, Exercisable		$ 7.82
Weighted Average Remaining Contractual Term (Years), Exercisable		5 years 2 months 8 days
Aggregate Intrinsic Value, Exercisable (in Dollars)		$ 3,980

Stockholders’ Equity (Details) - Schedule of Warrant Activities - Warrant [Member] - USD ($)		6 Months Ended
	Dec. 31, 2023	Jun. 30, 2024
Schedule of Warrant Activities [Line Items]
Number of Warrants, Beginning Balance	404,580
Weighted Average Exercise Price,Beginning Balance	$ 14.05
Weighted Average Remaining Contractual Term (Years).Beginning Balance	2 years 3 months 21 days	4 years 10 days
Aggregate Intrinsic Value, Beginning Balance
Number of Warrants, Granted		1,020,276
Weighted Average Exercise Price, Granted		$ 2.04
Weighted Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted
Number of Warrants, Exercised		(34,037)
Weighted Average Exercise Price, Exercised		$ 0.0001
Number of Warrants, Ending		1,390,819
Weighted Average Exercise Price, Ending		$ 5.58
Weighted Average Remaining Contractual Term (Years) Ending	2 years 3 months 21 days	4 years 10 days
Aggregate Intrinsic Value, Ending
Number of Warrants, Exercisable		1,390,819
Weighted Average Exercise Price, Exercisable		$ 5.58
Weighted Average Remaining Contractual Term (Years), Exercisable		4 years 10 days
Aggregate Intrinsic Value, Exercisable

Concentrations (Details) - Revenue Benchmark [Member]	6 Months Ended
Concentrations (Details) - Revenue Benchmark [Member]	Jun. 30, 2024	Jun. 30, 2023
Customer Concentration Risk [Member] \| One Licensee [Member]
Concentrations [Line Items]
Concentration risk percentage	100.00%	100.00%
Vendor Concentraion Risk [Member] \| Two Licensor [Member]
Concentrations [Line Items]
Concentration risk percentage	100.00%	100.00%

Commitments and Contingencies (Details)													1 Months Ended								3 Months Ended			6 Months Ended		12 Months Ended
Commitments and Contingencies (Details)	Jun. 28, 2024 USD ($)	Oct. 16, 2023 USD ($)	Oct. 16, 2023 GBP (£)	Oct. 25, 2022 USD ($)	Oct. 12, 2022 USD ($)	Aug. 31, 2022 USD ($)	Jan. 27, 2022 USD ($) $ / shares shares	Sep. 10, 2021 USD ($)	Sep. 01, 2021 USD ($)	Jun. 01, 2021 USD ($)	Apr. 12, 2021 USD ($) $ / shares shares	Jan. 05, 2021 USD ($) shares	Sep. 30, 2023 USD ($)	Aug. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Oct. 31, 2022 USD ($) shares	Jul. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)	Nov. 30, 2021 USD ($)	Apr. 30, 2021 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 31, 2023 shares	Sep. 30, 2021 USD ($)
Commitments and Contingencies [Line Items]
Amortized deferred compensation																						$ 8,474			$ 8,474
Research and development expenses																					$ 392,824	130,719		$ 774,889	333,632
UMB fee amount																									2,500
License agreement expire																								15 years
Percentage of sublicense income receivable																								25.00%
Prepaid expense and other current assets																					120,288			$ 120,288		$ 15,970
Sales of licensed products percentage																								5.00%
Sales																								$ 50,000,000
Initial license fee																					50,000			$ 50,000
Percentage of net sales																								2.00%
Royalty payment																								$ 500,000
Percentage of license fee																								5.00%
Unreimbursed Patent Expenses	$ 197,400																													$ 197,400
Accounts payable	$ 197,400
Deferred revenue																					1,676			$ 1,676		26,612
Cash																					3			3
Deferred revenue – current portion amounted																					72,102			72,102		72,102
Deferred revenue – long-term portion amounted																					757,629			757,629		793,680
Cash payments																							$ 430,825
Remaining amount due																										60,570
Amortization of the prepaid research and development fees																								$ 0	215,412
Percentage of estimate research																								90.00%
Accrued expenses																										5,891
Research remains to be billed																								$ 656,380
Research agreement																								67,720		0
Total fee																								654,510
Accounts payable related to this research agreement																					35,918			$ 35,918		0
Joint venture interest rate																								60.00%
Professional fees																					386,465	570,295		$ 641,067	935,565
Expected Term [Member]
Commitments and Contingencies [Line Items]
Expected term																								2 years
Research Agreements with Upperton Pharma Solutions [Member]
Commitments and Contingencies [Line Items]
Amortization of the prepaid research and development fees																								$ 181,944
AmplifyBio Research Agreements [Member]
Commitments and Contingencies [Line Items]
Amortization of the prepaid research and development fees																								119,340	0
License [Member]
Commitments and Contingencies [Line Items]
UMB fee amount																								75,000
Initial license fee																					25,000			$ 25,000
Patent Products [Member]
Commitments and Contingencies [Line Items]
Percentage of net sales																								4.00%
Eric Weisblum [Member]
Commitments and Contingencies [Line Items]
Base salary					$ 350,000
Signing bonus					100,000
Mr. Weisblum [Member]
Commitments and Contingencies [Line Items]
Annual bonus					200,000
Paid bonus													$ 200,000			$ 100,000
Daniel Ryweck [Member]
Commitments and Contingencies [Line Items]
Base salary					60,000
Dr. James Kuo [Member]
Commitments and Contingencies [Line Items]
Base salary							$ 30,000
Share granted (in Shares) \| shares							16,000
Exercisable per share (in Dollars per share) \| $ / shares							$ 10
Expire date							Jan. 31, 2032
Stock options (in Shares) \| shares							6,000
Vests (in Shares) \| shares																5,000													5,000
Stock option (in Shares) \| shares																								16,000
Fair value of stock option																								$ 94,915
Fair value of the unvested stock option																								$ 94,915
Dr. James Kuo [Member] \| Risk-Free interest Rate [Member]
Commitments and Contingencies [Line Items]
Risk-free interest rate																								1.18%
Dr. James Kuo [Member] \| Dividend Yield [Member]
Commitments and Contingencies [Line Items]
Expected dividend yield																								0.00%
Dr. James Kuo [Member] \| Expected Volatility [Member]
Commitments and Contingencies [Line Items]
Expected volatility																								117.00%
Dr. James Kuo [Member] \| Stock Options [Member]
Commitments and Contingencies [Line Items]
Amortized deferred compensation																					$ 0			$ 0
University of Maryland Baltimore [Member]
Commitments and Contingencies [Line Items]
UMB fee amount														$ 2,500											1,000
Extension Fee														2,500
University of Maryland Baltimore [Member] \| Third Amendment [Member]
Commitments and Contingencies [Line Items]
Research and development expenses																											$ 2,500
University of Maryland Baltimore [Member] \| Extension fee [Member]
Commitments and Contingencies [Line Items]
UMB fee amount															$ 1,000
University of Maryland Baltimore [Member] \| License [Member]
Commitments and Contingencies [Line Items]
UMB fee amount														2,500	$ 1,000
Master Lincense Agreement [Member]
Commitments and Contingencies [Line Items]
Commercial sale term																								10 years
Percentage of sublicense income receivable																								15.00%
Due amount																								$ 25,000
Paid amount																		$ 50,000
Term year																					15 years			15 years
Prepaid expense and other current assets																					$ 5,000			$ 5,000		5,000
Prepaid expenses non-current																					53,125			$ 53,125		55,625
Sales of licensed products percentage																								3.00%
Sales																								$ 50,000,000
License fees																								419	419
Master Lincense Agreement [Member] \| License [Member]
Commitments and Contingencies [Line Items]
UMB fee amount																								75,000
Sponsored Research Agreement with Columbia University [Member]
Commitments and Contingencies [Line Items]
Cash payments														$ 100,000										330,825		330,825
Amortization of the prepaid research and development fees																								$ 0	71,427
Sponsored research agreement, description																								the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project.
Accounts payable																					143,607			$ 143,607
Accrued expenses																					0			0
Sponsored Research Agreement with Columbia University [Member] \| License [Member]
Commitments and Contingencies [Line Items]
UMB fee amount																								2,500
Customer Patent License Agreement with Aikido Pharma Inc [Member]
Commitments and Contingencies [Line Items]
Non-refundable cash payment												$ 500,000												$ 500,000
Net sale percentage																								2.00%
Licensor share (in Shares) \| shares												500												500
Aggregate of converted shares (in Shares) \| shares												625,000												625,000
Revenue term												15 years												15 years
Common stock shares (in Shares) \| shares											625,000
Per share (in Dollars per share) \| $ / shares											$ 0.85
Trading price											$ 531,250
Equity investment											531,250
Deferred revenue											$ 531,250										1,031,250			$ 1,031,250
Cash																					500,000			500,000
Securities received																					531,250			531,250
Deferred revenue – current portion amounted																					68,750			68,750		68,750
Deferred revenue – long-term portion amounted																					721,875			$ 721,875		756,250
Consideration fee payable percentage																								110.00%
Customer Patent License Agreement with Aikido Pharma Inc [Member] \| License Fee Revenues [Member]
Commitments and Contingencies [Line Items]
Deferred revenue																					34,375	34,375		$ 34,375	34,375
Customer Sublicense Agreement with Aikido Pharma Inc [Member]
Commitments and Contingencies [Line Items]
UMB fee amount																				$ 50,000				1,900,000
Deferred revenue																					181,746	$ 1,676		181,746	1,676
Deferred revenue – current portion amounted																					3,352			3,352		3,352
Deferred revenue – long-term portion amounted																					35,754			35,754		37,430
Upfront license fees																								$ 50,000
First commercial sale																								10 years
Agreement shall expire																								15 years
Investigator-Sponsored Study Agreement with University of Maryland, Baltimore [Member]
Commitments and Contingencies [Line Items]
Research and development expenses																												$ 40,737
Sponsored study agreement												$ 40,737
Cash payments																												40,737
Sponsored Research Agreement with The Regents of the University of California [Member]
Commitments and Contingencies [Line Items]
UMB fee amount										$ 342,850
Prepaid expense and other current assets																											181,710	$ 100,570
Prepaid expense																										182,980
Sponsored Research Agreement with University of Maryland, Baltimore [Member]
Commitments and Contingencies [Line Items]
Cash payments						$ 92,095			$ 92,095
Accounts payable and accrued expenses																					92,095			$ 92,095		92,095
Research Agreement with Reprocell [Member]
Commitments and Contingencies [Line Items]
Research and development expenses																								0	13,944
UMB fee amount				$ 41,306
Prepaid expense and other current assets																											$ 21,172
Accounts payable and accrued expenses																					61,945			61,945		34,525
Research Agreements with Upperton Pharma Solutions [Member]
Commitments and Contingencies [Line Items]
Amortization of the prepaid research and development fees																									27,423
Aggregate total fee		$ 272,620	£ 216,210
Upperton Research Agreements [Member]
Commitments and Contingencies [Line Items]
Aggregate total fee																										177,903
AmplifyBio Research Agreement [Member]
Commitments and Contingencies [Line Items]
UMB fee amount																								958,700
Amortization of the prepaid research and development fees																								217,664	0
Sever Pharma [Member]
Commitments and Contingencies [Line Items]
Research remains to be billed																								452,241
Research Agreement with Sever Pharma Solutions [Member]
Commitments and Contingencies [Line Items]
Amortization of the prepaid research and development fees																								$ 18,472
Research Agreement with AmplifyBio [Member]
Commitments and Contingencies [Line Items]
Amortization of the prepaid research and development fees																									32,849
Joint Venture Agreement with Zylö Therapeutics, Inc [Member]
Commitments and Contingencies [Line Items]
Joint venture interest rate																								49.00%
Amended Service Agreement [Member]
Commitments and Contingencies [Line Items]
Payments to the university								$ 5,000
Professional fees																								$ 10,000	$ 15,000
Third Payment [Member]
Commitments and Contingencies [Line Items]
Initial license fee																					50,000			50,000
First Payment [Member] \| Sponsored Research Agreement with Columbia University [Member]
Commitments and Contingencies [Line Items]
Cash payments																			$ 430,825
Second Payment [Member] \| Sponsored Research Agreement with Columbia University [Member]
Commitments and Contingencies [Line Items]
Cash payments																	$ 430,825
Sublicense Agreement [Member]
Commitments and Contingencies [Line Items]
Prepaid expense and other current assets																										838
Prepaid expenses non-current																										$ 9,358
Sublicense income, percentage																				25.00%
Sublicense agreement amount paid																				$ 12,500
Sublicense Agreement [Member] \| Master Lincense Agreement [Member]
Commitments and Contingencies [Line Items]
Prepaid expense and other current assets																					838			838
Prepaid expenses non-current																					$ 8,939			8,939
Sponsored Study Agreement [Member]
Commitments and Contingencies [Line Items]
Installments payable												81,474
Sponsored Study Agreement [Member] \| Investigator-Sponsored Study Agreement with University of Maryland, Baltimore [Member]
Commitments and Contingencies [Line Items]
Installments payable												$ 40,737
JV Agreement [Member]
Commitments and Contingencies [Line Items]
Contribution cost																								$ 225,000
Joint venture interest rate																								51.00%
Option expired term																								24 months
Board of Directors [Member] \| Eric Weisblum [Member]
Commitments and Contingencies [Line Items]
Annual bonus					$ 350,000
Series M Convertible Preferred [Member]
Commitments and Contingencies [Line Items]
Convertible preferred stock (in Shares) \| shares											500

Commitments and Contingencies (Details) - Schedule of Milestone Payments	6 Months Ended
	Jun. 30, 2024 USD ($)
Payment One [Member]
Commitments and Contingencies (Details) - Schedule of Milestone Payments [Line Items]
Milestone	Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product
Payment	$ 50,000
Payment Two [Member]
Commitments and Contingencies (Details) - Schedule of Milestone Payments [Line Items]
Milestone	Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product
Payment	$ 100,000
Payment Three [Member]
Commitments and Contingencies (Details) - Schedule of Milestone Payments [Line Items]
Milestone	Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product
Payment	$ 250,000
Payment Four [Member]
Commitments and Contingencies (Details) - Schedule of Milestone Payments [Line Items]
Milestone	Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product
Payment	$ 500,000
Payment Five [Member]
Commitments and Contingencies (Details) - Schedule of Milestone Payments [Line Items]
Milestone	Achievement of First Commercial Sale of Licensed Product
Payment	$ 1,000,000

Commitments and Contingencies (Details) - Schedule of Minimum Annual Royalty Payments	6 Months Ended
	Jun. 30, 2024 USD ($)
Payment One [Member]
Schedule of Minimum Annual Royalty Payments [Line Items]
Years	Prior to First Commercial Sale
Minimum Annual Royalty
Payment Two [Member]
Schedule of Minimum Annual Royalty Payments [Line Items]
Years	Year of First Commercial Sale
Minimum Annual Royalty
Payment Three [Member]
Schedule of Minimum Annual Royalty Payments [Line Items]
Years	First calendar year following the First Commercial Sale
Minimum Annual Royalty	$ 25,000
Payment Four [Member]
Schedule of Minimum Annual Royalty Payments [Line Items]
Years	Second calendar year following the First Commercial Sale
Minimum Annual Royalty	$ 25,000
Payment Five [Member]
Schedule of Minimum Annual Royalty Payments [Line Items]
Years	Third calendar year following the First Commercial Sale
Minimum Annual Royalty	$ 100,000

Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees	6 Months Ended
	Jun. 30, 2024 USD ($)
Payment One [Member]
Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees [Line Items]
Payment	$ 92,095
Payment description	Paid upon execution of the July 2021 Sponsored Research Agreement
Payment Two [Member]
Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees [Line Items]
Payment	$ 92,095
Payment description	Paid six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement
Payment Three [Member]
Commitments and Contingencies (Details) - Schedule of Shall Pay UMB Fees [Line Items]
Payment	$ 92,095
Payment description	Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement

Commitments and Contingencies (Details) - Schedule of Future Amounts Due Under Sponsored Study and Research Agreements	Jun. 30, 2024 USD ($)
Schedule of Future Amounts Due Under Sponsored Study and Research Agreements [Abstract]
2025	$ 1,878,928
Total	$ 1,878,928

Subsequent Events (Details) - USD ($)					4 Months Ended	6 Months Ended
Subsequent Events (Details) - USD ($)	Jul. 31, 2024	Jul. 18, 2024	Jun. 04, 2024	Apr. 23, 2024	Apr. 23, 2024	Jun. 30, 2024
Subsequent Events [Line Items]
Purchase price per share (in Dollars per share)			$ 2.1799
Aggregate common warrants shares (in Shares)			917,432
Warrants exercise price (in Dollars per share)			$ 0.0001
Net proceeds					$ 1,673,216
Offering costs				$ 260,950	260,950
Legal expenses						$ 65,833
Cash fee equal percentage				7.50%
Percentage of management fee				1.00%
Aggregate number of shares				7.50%
Management fee			$ 170,000
Purchase Price (in Shares)			34,037
Exercise price percentage			125.00%
Placement Agent [Member]
Subsequent Events [Line Items]
Proceeds from offering						2,100,005
Net proceeds						1,780,555
Offering costs						269,450
Legal expenses					50,000
Purchase Price (in Shares)			68,807
Non accountable expenses					25,000
Clearing fees					$ 15,950
Common Warrant Shares [Member]
Subsequent Events [Line Items]
Aggregate common warrants shares (in Shares)			917,432
Warrants exercise price (in Dollars per share)			$ 2.06
Purchase Price (in Shares)			1
Common Warrant Shares [Member] \| Placement Agent [Member]
Subsequent Events [Line Items]
Legal expenses						$ 50,000
Subsequent Event [Member]
Subsequent Events [Line Items]
Investors amount (in Shares)		763,638
Purchase price per share (in Dollars per share)		$ 2.75
Aggregate common warrants shares (in Shares)	763,638
Warrants exercise price (in Dollars per share)	$ 2.75
Legal expenses		$ 50,000
Management fee		$ 178,500
Exercise price percentage		125.00%
Per share (in Dollars per share)		$ 3.4375
Non accountable expenses		$ 25,000
Clearing fees		$ 15,950
Common Stock [Member] \| Subsequent Event [Member]
Subsequent Events [Line Items]
Purchase Price (in Shares)		57,273